<Summary id="CDR0000683767"><SummaryMetaData><SummaryType>Integrative, alternative, and complementary therapies</SummaryType><SummaryAudience>Health professionals</SummaryAudience><SummaryLanguage>English</SummaryLanguage><SummaryDescription>Cannabis has been used medicinally for millennia, but has not been approved by the U.S. Food and Drug Administration to treat any medical condition. Cannabinoids are the components in cannabis; some are commercially available to treat symptoms. Get detailed information in this clinician summary.</SummaryDescription><SummaryURL xref="https://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq">Cannabis and Cannabinoids (PDQ®)</SummaryURL><SummaryToggleURL xref="https://www.cancer.gov/about-cancer/treatment/cam/patient/cannabis-pdq">Cannabis and Cannabinoids (PDQ®)</SummaryToggleURL><SummaryEditorialBoard ref="CDR0000256158">PDQ Integrative, Alternative, and Complementary Therapies Editorial Board</SummaryEditorialBoard><MainTopics><TermRef ref="CDR0000269131">marijuana</TermRef></MainTopics><MainTopics><TermRef ref="CDR0000572214">nabiximols</TermRef></MainTopics><SummaryAbstract><Para id="_253">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the use of  Cannabis and cannabinoids in the treatment of people with cancer. It is intended as a resource to inform and assist clinicians in the care of their patients. It does not provide formal guidelines or recommendations for making health care decisions.</Para><Para id="_254">This summary is reviewed regularly and updated as necessary by the PDQ Integrative, Alternative, and Complementary Therapies Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para></SummaryAbstract><SummaryKeyWords><SummaryKeyWord>marijuana</SummaryKeyWord><SummaryKeyWord>nabiximols</SummaryKeyWord></SummaryKeyWords></SummaryMetaData><SummaryTitle>Cannabis and Cannabinoids (PDQ®)–Health Professional Version</SummaryTitle><AltTitle TitleType="Browser">Cannabis and Cannabinoids (PDQ®)</AltTitle><AltTitle TitleType="CancerTypeHomePage">Cannabis and Cannabinoids</AltTitle><SummarySection id="_1"><Title>Overview</Title><Para id="_2">This <GlossaryTermRef href="CDR0000045333" dictionary="Cancer.gov" audience="Patient">cancer</GlossaryTermRef> information summary provides an overview of the use of <ScientificName><GlossaryTermRef href="CDR0000716285" dictionary="Cancer.gov" audience="Patient">Cannabis</GlossaryTermRef></ScientificName> and its components as a treatment for people with cancer-related <GlossaryTermRef href="CDR0000045022" dictionary="Cancer.gov" audience="Patient">symptoms</GlossaryTermRef> caused by the disease itself or  its treatment.</Para><Para id="_17">This summary contains the following key information:</Para><ItemizedList id="_18" Style="bullet"><ListItem><ScientificName>Cannabis</ScientificName> has been used for medicinal purposes for thousands of years.</ListItem><ListItem>By federal law, the possession of <ScientificName>Cannabis</ScientificName> is illegal in the United States, except within approved research settings; however, a growing number of states, territories, and the District of Columbia have enacted laws to legalize its medical and/or recreational use.</ListItem><ListItem>The U.S. Food and Drug Administration has not approved <ScientificName>Cannabis</ScientificName> as a treatment for cancer or any other medical condition.</ListItem><ListItem><GlossaryTermRef href="CDR0000643008" dictionary="Cancer.gov" audience="Patient">Chemical</GlossaryTermRef> components of <ScientificName>Cannabis</ScientificName>, called <GlossaryTermRef href="CDR0000716077" dictionary="Cancer.gov" audience="Patient">cannabinoids</GlossaryTermRef>, <GlossaryTermRef href="CDR0000043976" dictionary="Cancer.gov" audience="Patient">activate</GlossaryTermRef> specific <GlossaryTermRef href="CDR0000044958" dictionary="Cancer.gov" audience="Patient">receptors</GlossaryTermRef> throughout the body to produce <GlossaryTermRef href="CDR0000463167" dictionary="Cancer.gov" audience="Patient">pharmacological</GlossaryTermRef> effects, particularly in the <GlossaryTermRef href="CDR0000046481" dictionary="Cancer.gov" audience="Patient">central nervous system</GlossaryTermRef>  and the <GlossaryTermRef href="CDR0000046356" dictionary="Cancer.gov" audience="Patient">immune system</GlossaryTermRef>.</ListItem><ListItem>Commercially available cannabinoids, such as <GlossaryTermRef href="CDR0000045240" dictionary="Cancer.gov" audience="Patient">dronabinol</GlossaryTermRef> and <GlossaryTermRef href="CDR0000716290" dictionary="Cancer.gov" audience="Patient">nabilone</GlossaryTermRef>,  are approved drugs for the treatment of cancer-related <GlossaryTermRef href="CDR0000046580" dictionary="Cancer.gov" audience="Patient">side effects</GlossaryTermRef>.</ListItem><ListItem>Cannabinoids may have benefits in the treatment of cancer-related side effects.</ListItem></ItemizedList><Para id="_79">Many of the medical and scientific terms used in this summary are hypertext linked (at first use in each section) to the <ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-terms/">NCI Dictionary of Cancer Terms</ExternalRef>, which is oriented toward nonexperts. When a linked term is clicked, a definition will appear in a separate window. </Para><Para id="_80">Reference citations in some <GlossaryTermRef href="CDR0000044271" dictionary="Cancer.gov" audience="Patient">PDQ</GlossaryTermRef> cancer information summaries may include links to external websites that are operated by individuals or organizations for the purpose of marketing or advocating the use of specific treatments or products. These reference citations are included for informational purposes only. Their inclusion should not be viewed as an endorsement of the content of the websites, or of any treatment or product, by the PDQ Integrative, Alternative, and Complementary Therapies Editorial Board or the <GlossaryTermRef href="CDR0000044266" dictionary="Cancer.gov" audience="Patient">National Cancer Institute</GlossaryTermRef>.</Para></SummarySection><SummarySection id="_3"><Title>General Information</Title><Para id="_4"><ScientificName><GlossaryTermRef href="CDR0000716285" dictionary="Cancer.gov" audience="Patient">Cannabis</GlossaryTermRef></ScientificName>, also known as <GlossaryTermRef href="CDR0000285927" dictionary="Cancer.gov" audience="Patient">marijuana</GlossaryTermRef>, originated in Central Asia but is grown worldwide today.  In the United States, it is a <GlossaryTermRef href="CDR0000716287" dictionary="Cancer.gov" audience="Patient">controlled substance</GlossaryTermRef> and is classified as a <GlossaryTermRef href="CDR0000797085" dictionary="Cancer.gov" audience="Patient">Schedule I agent</GlossaryTermRef> (a <GlossaryTermRef href="CDR0000348921" dictionary="Cancer.gov" audience="Patient">drug</GlossaryTermRef> with a high potential for abuse, and no currently accepted medical use).    The <ScientificName>Cannabis</ScientificName> plant produces a <GlossaryTermRef href="CDR0000642508" dictionary="Cancer.gov" audience="Patient">resin</GlossaryTermRef> containing 21-carbon terpenophenolic <GlossaryTermRef href="CDR0000422394" dictionary="Cancer.gov" audience="Patient">compounds</GlossaryTermRef> called <GlossaryTermRef href="CDR0000716077" dictionary="Cancer.gov" audience="Patient">cannabinoids</GlossaryTermRef>, in addition to other compounds found in plants, such as <GlossaryTermRef href="CDR0000463097" dictionary="Cancer.gov" audience="Patient">terpenes</GlossaryTermRef> and <GlossaryTermRef href="CDR0000330168" dictionary="Cancer.gov" audience="Patient">flavonoids</GlossaryTermRef>.  The highest <GlossaryTermRef href="CDR0000683342" dictionary="Cancer.gov" audience="Patient">concentration</GlossaryTermRef> of cannabinoids is found in the female flowers of the plant.<Reference refidx="1"/> Delta-9-tetrahydrocannabinol (THC) is the main psychoactive cannabinoid, but over 100 other cannabinoids have been reported to be present in the plant. Cannabidiol (CBD) does not produce the characteristic <GlossaryTermRef href="CDR0000044643" dictionary="Cancer.gov" audience="Patient">altered</GlossaryTermRef> consciousness associated with <ScientificName>Cannabis</ScientificName>. CBD is thought to have potential <GlossaryTermRef href="CDR0000043985" dictionary="Cancer.gov" audience="Patient">therapeutic</GlossaryTermRef> effectiveness and has recently been approved in the form of the pharmaceutical Epidiolex for the treatment of <GlossaryTermRef href="CDR0000350245" dictionary="Cancer.gov" audience="Patient">refractory</GlossaryTermRef> <GlossaryTermRef href="CDR0000045484" dictionary="Cancer.gov" audience="Patient">seizure</GlossaryTermRef> <GlossaryTermRef href="CDR0000407758" dictionary="Cancer.gov" audience="Patient">disorders</GlossaryTermRef> in children. Other cannabinoids that are being investigated for potential medical benefits include cannabinol (CBN), cannabigerol (CBG), and tetrahydrocannabivarin (THCV).  </Para><Para id="_344"><GlossaryTermRef href="CDR0000045961" dictionary="Cancer.gov" audience="Patient">Clinical trials</GlossaryTermRef> conducted on medicinal <ScientificName>Cannabis</ScientificName> are limited. The <GlossaryTermRef href="CDR0000454785" dictionary="Cancer.gov" audience="Patient">U.S. Food and Drug Administration</GlossaryTermRef>  (FDA) has not approved the use of <ScientificName>Cannabis</ScientificName> as a treatment for any medical <GlossaryTermRef href="CDR0000651193" dictionary="Cancer.gov" audience="Patient">condition</GlossaryTermRef>, although both isolated THC and CBD pharmaceuticals are licensed and approved. To conduct <GlossaryTermRef href="CDR0000044168" dictionary="Cancer.gov" audience="Patient">clinical</GlossaryTermRef> <GlossaryTermRef href="CDR0000348921" dictionary="Cancer.gov" audience="Patient">drug</GlossaryTermRef> research with <GlossaryTermRef href="CDR0000367458" dictionary="Cancer.gov" audience="Patient">botanical</GlossaryTermRef> <ScientificName>Cannabis</ScientificName> in the United States, researchers must file an <GlossaryTermRef href="CDR0000762975" dictionary="Cancer.gov" audience="Patient">Investigational New Drug</GlossaryTermRef> (IND) application with the FDA, obtain a Schedule I license from the U.S. Drug Enforcement Administration, and obtain approval from the National Institute on Drug Abuse.</Para><Para id="_315">In the 2018 United States Farm Bill, the term <Emphasis>hemp</Emphasis> is used to describe cultivars of the <ScientificName>Cannabis</ScientificName> species that contain less than 0.3% THC.  

<Emphasis>Hemp oil</Emphasis> or CBD oil are products manufactured from <GlossaryTermRef href="CDR0000407760" dictionary="Cancer.gov" audience="Patient">extracts</GlossaryTermRef> of industrial hemp (i.e., low-THC <ScientificName>cannabis</ScientificName> cultivars), whereas <Emphasis>hemp seed oil</Emphasis> is an edible fatty oil that is essentially cannabinoid-free (see <SummaryRef href="CDR0000683767#_331" url="/about-cancer/treatment/cam/hp/cannabis-pdq">Table 1</SummaryRef>). Some products contain  other botanical extracts and/or <GlossaryTermRef href="CDR0000044696" dictionary="Cancer.gov" audience="Patient">over-the-counter</GlossaryTermRef>  <GlossaryTermRef href="CDR0000045590" dictionary="Cancer.gov" audience="Patient">analgesics</GlossaryTermRef>. These products are readily available  as <GlossaryTermRef href="CDR0000044068" dictionary="Cancer.gov" audience="Patient">oral</GlossaryTermRef> and <GlossaryTermRef href="CDR0000045927" dictionary="Cancer.gov" audience="Patient">topical</GlossaryTermRef> <Emphasis>tinctures</Emphasis> or other formulations often advertised for pain management and other purposes. Hemp  products containing less than 0.3% of delta-9-THC are not scheduled drugs and could be considered as Farm Bill compliant. While CBD is a controlled substance, hemp is not.</Para><Table id="_331"><Title>Table 1.  Medicinal <Emphasis>Cannabis</Emphasis> Products—Guide to Terminology</Title><TGroup Cols="3"><ColSpec ColName="col1" ColNum="1" ColWidth="18.97%"/><ColSpec ColName="col02" ColNum="2" ColWidth="51.99%"/><ColSpec ColName="col2" ColNum="3" ColWidth="29.03%"/><THead><Row><entry Align="Center" NameEnd="col02" NameSt="col1">Name/Material</entry><entry Align="Center">Constituents/Composition</entry></Row></THead><TFoot><Row><entry NameEnd="col2" NameSt="col1">CBD =  cannabidiol; THC = tetrahydrocannabinol.</entry></Row></TFoot><TBody><Row><entry NameEnd="col02" NameSt="col1"><Emphasis>Cannabis</Emphasis> species,
including <ScientificName>C. sativa</ScientificName>
</entry><entry>Cannabinoids;
also terpenoids and flavonoids</entry></Row><Row><entry/><entry>•	Hemp
(aka industrial hemp)
</entry><entry>Low Δ<Superscript>9</Superscript>-THC (&lt;0.3%); high CBD</entry></Row><Row><entry/><entry>•	Marijuana/marihuana</entry><entry>High Δ<Superscript>9</Superscript>-THC (&gt;0.3%); low CBD</entry></Row><Row><entry NameEnd="col02" NameSt="col1"> Nabiximols (trade name: Sativex)</entry><entry>Mixture of ethanol extracts of <Emphasis>Cannabis</Emphasis> species; contains Δ<Superscript>9</Superscript>-THC and CBD in a 1:1 ratio</entry></Row><Row><entry NameEnd="col02" NameSt="col1">Hemp oil/CBD oil</entry><entry>Solution of a <GlossaryTermRef href="CDR0000463162" dictionary="Cancer.gov" audience="Patient">solvent</GlossaryTermRef> extract from <Emphasis>Cannabis</Emphasis> flowers and/or leaves dissolved in an edible oil; typically contains 1%–5% CBD</entry></Row><Row><entry NameEnd="col02" NameSt="col1">Hemp seed oil</entry><entry>Edible, fatty oil produced from <Emphasis>Cannabis</Emphasis> seeds; contains no or only traces of cannabinoids</entry></Row><Row><entry NameEnd="col02" NameSt="col1"><GlossaryTermRef href="CDR0000045240" dictionary="Cancer.gov" audience="Patient">Dronabinol</GlossaryTermRef> (trade names: Marinol and Syndros)</entry><entry><GlossaryTermRef href="CDR0000462950" dictionary="Cancer.gov" audience="Patient">Synthetic</GlossaryTermRef> Δ<Superscript>9</Superscript>-THC</entry></Row><Row><entry NameEnd="col02" NameSt="col1"><GlossaryTermRef href="CDR0000716290" dictionary="Cancer.gov" audience="Patient">Nabilone</GlossaryTermRef>  (trade names: <GlossaryTermRef href="CDR0000727111" dictionary="Cancer.gov" audience="Patient">Cesamet</GlossaryTermRef> and Canemes) </entry><entry>Synthetic THC <GlossaryTermRef href="CDR0000044919" dictionary="Cancer.gov" audience="Patient">analogue</GlossaryTermRef></entry></Row><Row><entry NameEnd="col02" NameSt="col1">Cannabidiol (trade name: Epidiolex)</entry><entry>Highly purified (&gt;98%), plant-derived CBD </entry></Row></TBody></TGroup></Table><Para id="_19">The potential benefits of medicinal <ScientificName>Cannabis</ScientificName> for people living with <GlossaryTermRef href="CDR0000045333" dictionary="Cancer.gov" audience="Patient">cancer</GlossaryTermRef> include the following:<Reference refidx="2"/> </Para><ItemizedList id="_333" Style="bullet">
     <ListItem><GlossaryTermRef href="CDR0000046084" dictionary="Cancer.gov" audience="Patient">Antiemetic</GlossaryTermRef> effects.</ListItem><ListItem><GlossaryTermRef href="CDR0000454699" dictionary="Cancer.gov" audience="Patient">Appetite</GlossaryTermRef> stimulation.</ListItem><ListItem>Pain relief.</ListItem><ListItem>Improved sleep.</ListItem></ItemizedList><Para id="_408">A study of 13,180 patients with various cancers treated at 12 NCI-designated cancer centers revealed important insights into the <GlossaryTermRef href="CDR0000789737" dictionary="Cancer.gov" audience="Patient">prevalence</GlossaryTermRef>, patterns, and perceptions of <ScientificName>Cannabis</ScientificName> use among people with cancer.<Reference refidx="3"/> Estimates of frequency of use were obtained in a subset of 12,614 respondents from the 10 sites that drew probability samples, with 33% of the respondents reporting <ScientificName>Cannabis</ScientificName> use since their cancer <GlossaryTermRef href="CDR0000046450" dictionary="Cancer.gov" audience="Patient">diagnoses</GlossaryTermRef>. Reported use showed little variation based on state legal status of <ScientificName>Cannabis</ScientificName>, with 26% usage reported in the one survey site in a state where <ScientificName>Cannabis</ScientificName> was fully illegal. Nearly 90% of <ScientificName>Cannabis</ScientificName>-using respondents reported various benefits: pain management (75%), better sleep (67%), nausea relief (65%), and improved appetite (56%). Sixty-five percent of patients with cancer reported some <GlossaryTermRef href="CDR0000044922" dictionary="Cancer.gov" audience="Patient">adverse effects</GlossaryTermRef> such as inability to drive, difficulty concentrating, <GlossaryTermRef href="CDR0000270740" dictionary="Cancer.gov" audience="Patient">lung</GlossaryTermRef> damage, and <GlossaryTermRef href="CDR0000454756" dictionary="Cancer.gov" audience="Patient">impaired</GlossaryTermRef> memory. Reported risks of <GlossaryTermRef href="CDR0000044639" dictionary="Cancer.gov" audience="Patient">addiction</GlossaryTermRef> and legal problems were more common in states where <ScientificName>Cannabis</ScientificName> was fully illegal. While 70% of patients expressed interest in learning more about medical <ScientificName>Cannabis</ScientificName>, only 21.5% discussed it with their cancer providers, and 15% reported receiving guidance from their healthcare team. The study highlights a significant gap between patient interest and provider engagement, emphasizing the need for better education and communication about <ScientificName>Cannabis</ScientificName> use in <GlossaryTermRef href="CDR0000045434" dictionary="Cancer.gov" audience="Patient">oncology</GlossaryTermRef> care.</Para><Para id="_404"> Although few relevant surveys of practice patterns exist, it appears that <GlossaryTermRef href="CDR0000390246" dictionary="Cancer.gov" audience="Patient">physicians</GlossaryTermRef> caring for patients with cancer in the United States recommend medicinal <ScientificName>Cannabis</ScientificName> primarily for <GlossaryTermRef href="CDR0000269453" dictionary="Cancer.gov" audience="Patient">symptom management</GlossaryTermRef>.<Reference refidx="4"/></Para><Para id="_20">This summary will review the role of <ScientificName>Cannabis</ScientificName> and the cannabinoids in the treatment of people with cancer and  disease-related or treatment-related <GlossaryTermRef href="CDR0000046580" dictionary="Cancer.gov" audience="Patient">side effects</GlossaryTermRef>. The NCI hosted a virtual meeting, the NCI Cannabis, Cannabinoids, and Cancer Research Symposium,  on December 15–18, 2020. The seven sessions are summarized in the <ExternalRef xref="https://academic.oup.com/jncimono/article/2021/58/35/6446198?login=true">Journal of the National Cancer Institute Monographs</ExternalRef> and contain basic science and clinical information as well as a summary of the barriers to conducting <ScientificName>Cannabis</ScientificName> research.<Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/><Reference refidx="9"/><Reference refidx="10"/><Reference refidx="11"/></Para><ReferenceSection><Citation idx="1" PMID="8972919">Adams IB, Martin BR: Cannabis: pharmacology and toxicology in animals and humans. Addiction 91 (11): 1585-614, 1996.</Citation><Citation idx="2" PMID="27022315">Abrams DI: Integrating cannabis into clinical cancer care. Curr Oncol 23 (2): S8-S14, 2016.</Citation><Citation idx="3" PMID="39108244">Ellison GL, Helzlsouer KJ, Rosenfield SM, et al.: Perceptions, prevalence, and patterns of cannabis use among cancer patients treated at 12 NCI-Designated Cancer Centers. J Natl Cancer Inst Monogr 2024 (66): 202-217, 2024.</Citation><Citation idx="4" PMID="2045870">Doblin RE, Kleiman MA: Marijuana as antiemetic medicine: a survey of oncologists' experiences and attitudes. J Clin Oncol 9 (7): 1314-9, 1991.</Citation><Citation idx="5" PMID="34850895">Ellison GL, Alejandro Salicrup L, Freedman AN, et al.: The National Cancer Institute and Cannabis and Cannabinoids Research. J Natl Cancer Inst Monogr 2021 (58): 35-38, 2021.</Citation><Citation idx="6" PMID="34850897">Sexton M, Garcia JM, Jatoi A, et al.: The Management of Cancer Symptoms and Treatment-Induced Side Effects With Cannabis or Cannabinoids. J Natl Cancer Inst Monogr 2021 (58): 86-98, 2021.</Citation><Citation idx="7" PMID="34850896">Cooper ZD, Abrams DI, Gust S, et al.: Challenges for Clinical Cannabis and Cannabinoid Research in the United States. J Natl Cancer Inst Monogr 2021 (58): 114-122, 2021.</Citation><Citation idx="8" PMID="34850899">Braun IM, Abrams DI, Blansky SE, et al.: Cannabis and the Cancer Patient. J Natl Cancer Inst Monogr 2021 (58): 68-77, 2021.</Citation><Citation idx="9" PMID="34850893">Ward SJ, Lichtman AH, Piomelli D, et al.: Cannabinoids and Cancer Chemotherapy-Associated Adverse Effects. J Natl Cancer Inst Monogr 2021 (58): 78-85, 2021.</Citation><Citation idx="10" PMID="34850900">McAllister SD, Abood ME, Califano J, et al.: Cannabinoid Cancer Biology and Prevention. J Natl Cancer Inst Monogr 2021 (58): 99-106, 2021.</Citation><Citation idx="11" PMID="34850894">Abrams DI, Velasco G, Twelves C, et al.: Cancer Treatment: Preclinical &amp; Clinical. J Natl Cancer Inst Monogr 2021 (58): 107-113, 2021.</Citation></ReferenceSection></SummarySection><SummarySection id="_5"><Title>History</Title><Para id="_6"><ScientificName><GlossaryTermRef href="CDR0000716285" dictionary="Cancer.gov" audience="Patient">Cannabis</GlossaryTermRef></ScientificName> use for medicinal purposes dates back at least 3,000 years.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/> It was introduced into <GlossaryTermRef href="CDR0000454743" dictionary="Cancer.gov" audience="Patient">Western medicine</GlossaryTermRef> in 1839 by W.B. O’Shaughnessy, a <GlossaryTermRef href="CDR0000044306" dictionary="Cancer.gov" audience="Patient">surgeon</GlossaryTermRef> who learned of its medicinal properties while working in India for the British East India Company.  Its use was promoted for reported <GlossaryTermRef href="CDR0000045590" dictionary="Cancer.gov" audience="Patient">analgesic</GlossaryTermRef>, <GlossaryTermRef href="CDR0000450118" dictionary="Cancer.gov" audience="Patient">sedative</GlossaryTermRef>, <GlossaryTermRef href="CDR0000044187" dictionary="Cancer.gov" audience="Patient">anti-inflammatory</GlossaryTermRef>, antispasmodic, and <GlossaryTermRef href="CDR0000046083" dictionary="Cancer.gov" audience="Patient">anticonvulsant</GlossaryTermRef> effects.</Para><Para id="_21">In 1937, the U.S. Treasury Department introduced the Marihuana Tax Act.  This Act imposed a levy of $1 per <GlossaryTermRef href="CDR0000330174" dictionary="Cancer.gov" audience="Patient">ounce</GlossaryTermRef> for medicinal use of <ScientificName>Cannabis</ScientificName> and $100 per ounce for nonmedical use.    <GlossaryTermRef href="CDR0000390246" dictionary="Cancer.gov" audience="Patient">Physicians</GlossaryTermRef> in the United States were the principal opponents of the Act. The American Medical Association (AMA) opposed the Act because physicians were required to pay a special tax for <GlossaryTermRef href="CDR0000044711" dictionary="Cancer.gov" audience="Patient">prescribing</GlossaryTermRef> <ScientificName>Cannabis</ScientificName>,  use special order forms to procure it, and  keep special records concerning its professional use. In addition, the AMA believed that objective evidence that <ScientificName>Cannabis</ScientificName> was harmful was lacking and that passage of the Act would impede further research into its medicinal worth.<Reference refidx="6"/>  In 1942, <ScientificName>Cannabis</ScientificName> was removed from the U.S. <GlossaryTermRef href="CDR0000285980" dictionary="Cancer.gov" audience="Patient">Pharmacopoeia</GlossaryTermRef> because of persistent concerns about its potential to cause harm.<Reference refidx="2"/><Reference refidx="3"/> Recently, there has been renewed interest in <ScientificName>Cannabis</ScientificName> by the U.S. Pharmacopeia.<Reference refidx="7"/></Para><Para id="_22">In 1951, Congress passed the Boggs Act, which for the first time included <ScientificName>Cannabis</ScientificName> with <GlossaryTermRef href="CDR0000044691" dictionary="Cancer.gov" audience="Patient">narcotic</GlossaryTermRef> <GlossaryTermRef href="CDR0000348921" dictionary="Cancer.gov" audience="Patient">drugs</GlossaryTermRef>. In 1970, with the passage of the Controlled Substances Act, <GlossaryTermRef href="CDR0000285927" dictionary="Cancer.gov" audience="Patient">marijuana</GlossaryTermRef> was classified by Congress as a <GlossaryTermRef href="CDR0000797085" dictionary="Cancer.gov" audience="Patient">Schedule I drug</GlossaryTermRef>.  Drugs in Schedule I are distinguished as having no currently accepted medicinal use in the United States.  Other Schedule I substances include <GlossaryTermRef href="CDR0000641798" dictionary="Cancer.gov" audience="Patient">heroin</GlossaryTermRef>, LSD, mescaline, and methaqualone.</Para><Para id="_23">Despite  its designation as having no medicinal use, <ScientificName>Cannabis</ScientificName>  was distributed by the U.S. government to patients on a case-by-case basis under the <GlossaryTermRef href="CDR0000046526" dictionary="Cancer.gov" audience="Patient">Compassionate Use</GlossaryTermRef> <GlossaryTermRef href="CDR0000762975" dictionary="Cancer.gov" audience="Patient">Investigational New Drug</GlossaryTermRef>  program established in 1978.  Distribution of <ScientificName>Cannabis</ScientificName> through this program was closed to new patients in 1992.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/> Although federal law prohibits the use of <ScientificName>Cannabis</ScientificName>, <SummaryRef href="CDR0000683767#_250" url="/about-cancer/treatment/cam/hp/cannabis-pdq">Figure 1</SummaryRef> below shows the states and territories that have legalized <ScientificName>Cannabis</ScientificName> use for medical purposes. Additional states have legalized only one ingredient in <ScientificName>Cannabis</ScientificName>, such as cannabidiol (CBD), and are not included in the map. Some medical marijuana laws are broader than others, and there is state-to-state variation in the types of medical conditions for which treatment is allowed.<Reference refidx="8"/></Para><MediaLink ref="CDR0000774100" type="image/jpeg" alt="A map showing the U.S. states and territories that have approved the medical use of Cannabis." language="en" placement="image-center" id="_250"><Caption language="en">Figure 1.  A map showing the U.S. states and territories that have approved the medical use of <ScientificName>Cannabis</ScientificName>. Last reviewed: 10/22/2024</Caption></MediaLink><Para id="_24">The main psychoactive constituent of <ScientificName>Cannabis</ScientificName> was identified as delta-9-tetrahydrocannabinol (THC).  In 1986, an <GlossaryTermRef href="CDR0000373084" dictionary="Cancer.gov" audience="Patient">isomer</GlossaryTermRef> of <GlossaryTermRef href="CDR0000462950" dictionary="Cancer.gov" audience="Patient">synthetic</GlossaryTermRef> delta-9-THC in sesame oil was licensed and approved for the treatment of <GlossaryTermRef href="CDR0000045214" dictionary="Cancer.gov" audience="Patient">chemotherapy</GlossaryTermRef>-associated <GlossaryTermRef href="CDR0000390302" dictionary="Cancer.gov" audience="Patient">nausea</GlossaryTermRef> and <GlossaryTermRef href="CDR0000390324" dictionary="Cancer.gov" audience="Patient">vomiting</GlossaryTermRef> under the <GlossaryTermRef href="CDR0000044672" dictionary="Cancer.gov" audience="Patient">generic</GlossaryTermRef> name <GlossaryTermRef href="CDR0000045240" dictionary="Cancer.gov" audience="Patient">dronabinol</GlossaryTermRef>.  <GlossaryTermRef href="CDR0000045961" dictionary="Cancer.gov" audience="Patient">Clinical trials</GlossaryTermRef> determined that dronabinol was as effective as or better than other <GlossaryTermRef href="CDR0000046084" dictionary="Cancer.gov" audience="Patient">antiemetic</GlossaryTermRef> agents available at the time.<Reference refidx="9"/>  Dronabinol was also studied for its ability to stimulate weight gain in patients with  <GlossaryTermRef href="CDR0000045950" dictionary="Cancer.gov" audience="Patient">AIDS</GlossaryTermRef> in the late 1980s.  Thus, the indications were expanded to include treatment of <GlossaryTermRef href="CDR0000044103" dictionary="Cancer.gov" audience="Patient">anorexia</GlossaryTermRef> associated with <GlossaryTermRef href="CDR0000044366" dictionary="Cancer.gov" audience="Patient">human immunodeficiency virus</GlossaryTermRef> <GlossaryTermRef href="CDR0000045364" dictionary="Cancer.gov" audience="Patient">infection</GlossaryTermRef>  in 1992. Clinical trial results showed no statistically <GlossaryTermRef href="CDR0000390271" dictionary="Cancer.gov" audience="Patient">significant</GlossaryTermRef> weight gain, although patients reported an improvement in <GlossaryTermRef href="CDR0000454699" dictionary="Cancer.gov" audience="Patient">appetite</GlossaryTermRef>.<Reference refidx="10"/><Reference refidx="11"/> Another important <GlossaryTermRef href="CDR0000716077" dictionary="Cancer.gov" audience="Patient">cannabinoid</GlossaryTermRef> found in <ScientificName>Cannabis</ScientificName> is CBD.<Reference refidx="12"/>
  This is a nonpsychoactive cannabinoid, which is an <GlossaryTermRef href="CDR0000044919" dictionary="Cancer.gov" audience="Patient">analogue</GlossaryTermRef> of THC.</Para><Para id="_25">In recent decades, the neurobiology of  cannabinoids has been analyzed.<Reference refidx="13"/><Reference refidx="14"/><Reference refidx="15"/><Reference refidx="16"/> The first cannabinoid <GlossaryTermRef href="CDR0000044958" dictionary="Cancer.gov" audience="Patient">receptor</GlossaryTermRef>, CB1, was identified in the brain in 1988.  A second cannabinoid receptor, CB2, was identified  in 1993. The highest expression of CB2 receptors is located on <GlossaryTermRef href="CDR0000044953" dictionary="Cancer.gov" audience="Patient">B lymphocytes</GlossaryTermRef> and <GlossaryTermRef href="CDR0000044062" dictionary="Cancer.gov" audience="Patient">natural killer cells</GlossaryTermRef>, suggesting a possible role in <GlossaryTermRef href="CDR0000468803" dictionary="Cancer.gov" audience="Patient">immunity</GlossaryTermRef>.  <GlossaryTermRef href="CDR0000044026" dictionary="Cancer.gov" audience="Patient">Endogenous</GlossaryTermRef> cannabinoids (endocannabinoids) have been identified and appear to have a role in pain modulation, control of movement, feeding behavior, mood, bone growth, <GlossaryTermRef href="CDR0000044042" dictionary="Cancer.gov" audience="Patient">inflammation</GlossaryTermRef>, neuroprotection, and memory.<Reference refidx="17"/></Para><Para id="_202">Nabiximols (Sativex), a <ScientificName>Cannabis</ScientificName> <GlossaryTermRef href="CDR0000407760" dictionary="Cancer.gov" audience="Patient">extract</GlossaryTermRef> with a 1:1 ratio of THC:CBD, is approved in Canada (under the Notice of Compliance with Conditions) for symptomatic relief of pain in advanced cancer and <GlossaryTermRef href="CDR0000044135" dictionary="Cancer.gov" audience="Patient">multiple sclerosis</GlossaryTermRef>.<Reference refidx="18"/> Nabiximols is an <GlossaryTermRef href="CDR0000463714" dictionary="Cancer.gov" audience="Patient">herbal</GlossaryTermRef> preparation containing a defined quantity of specific cannabinoids formulated for oromucosal spray <GlossaryTermRef href="CDR0000478733" dictionary="Cancer.gov" audience="Patient">administration</GlossaryTermRef> with potential analgesic activity. Nabiximols contains extracts from two <ScientificName>Cannabis</ScientificName> plant varieties. The extracts mixture is standardized to the <GlossaryTermRef href="CDR0000683342" dictionary="Cancer.gov" audience="Patient">concentrations</GlossaryTermRef> of the psychoactive delta-9-THC and the nonpsychoactive CBD. The preparation also contains other, more minor cannabinoids, <GlossaryTermRef href="CDR0000330168" dictionary="Cancer.gov" audience="Patient">flavonoids</GlossaryTermRef>, and terpenoids.<Reference refidx="19"/>  Canada, New Zealand, and most countries in western Europe also have approved nabiximols for spasticity of multiple sclerosis, a common symptom that may include muscle stiffness, reduced mobility, and pain, and for which existing therapy is unsatisfactory.</Para><ReferenceSection><Citation idx="1">Abel EL: Marihuana, The First Twelve Thousand Years. Plenum Press, 1980. <ExternalRef xref="https://www.druglibrary.org/Schaffer/hemp/history/first12000/abel.htm">Also available online</ExternalRef>. Last accessed June 2, 2021.</Citation><Citation idx="2">Joy JE, Watson SJ, Benson JA, eds.: Marijuana and Medicine: Assessing the Science Base. National Academy Press, 1999. <ExternalRef xref="https://www.nap.edu/read/6376/chapter/1">Also available online</ExternalRef>. Last accessed June 2, 2021.</Citation><Citation idx="3">Mack A, Joy J: Marijuana As Medicine? The Science Beyond the Controversy. National Academy Press, 2001. <ExternalRef xref="https://www.nap.edu/read/9586/chapter/1">Also available online</ExternalRef>. Last accessed June 2, 2021.</Citation><Citation idx="4">Booth M: Cannabis: A History. St Martin's Press, 2003.</Citation><Citation idx="5" PMID="19036842">Russo EB, Jiang HE, Li X, et al.: Phytochemical and genetic analyses of ancient cannabis from Central Asia. J Exp Bot 59 (15): 4171-82, 2008.</Citation><Citation idx="6">Schaffer Library of Drug Policy: The Marihuana Tax Act of 1937: Taxation of Marihuana. Washington, DC: House of Representatives, Committee on Ways and Means, 1937. <ExternalRef xref="https://www.druglibrary.org/schaffer/hemp/taxact/woodward.htm">Available online</ExternalRef>.   Last accessed June 2, 2021.</Citation><Citation idx="7" PMID="32281793">Sarma ND, Waye A, ElSohly MA, et al.: Cannabis Inflorescence for Medical Purposes: USP Considerations for Quality Attributes. J Nat Prod 83 (4): 1334-1351, 2020.</Citation><Citation idx="8">National Academies of Sciences, Engineering, and Medicine: The Health Effects of Cannabis and Cannabinoids:  The Current State of Evidence and Recommendations for Research. The National Academies Press, 2017.</Citation><Citation idx="9" PMID="1099449" MedlineID="76010695">Sallan SE, Zinberg NE, Frei E: Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med 293 (16): 795-7, 1975.</Citation><Citation idx="10" PMID="1311935">Gorter R, Seefried M, Volberding P: Dronabinol effects on weight in patients with HIV infection. AIDS 6 (1): 127, 1992.</Citation><Citation idx="11" PMID="7730690">Beal JE, Olson R, Laubenstein L, et al.: Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 10 (2): 89-97, 1995.</Citation><Citation idx="12">Adams R, Hunt M, Clark JH: Structure of cannabidiol: a product isolated from the marihuana extract of Minnesota wild hemp. J Am Chem Soc  62 (1): 196-200, 1940. <ExternalRef xref="https://pubs.acs.org/doi/abs/10.1021/ja01858a058">Also available online</ExternalRef>. Last accessed June 2, 2021.</Citation><Citation idx="13" PMID="2848184">Devane WA, Dysarz FA, Johnson MR, et al.: Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34 (5): 605-13, 1988.</Citation><Citation idx="14" PMID="1470919">Devane WA, Hanus L, Breuer A, et al.: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 (5090): 1946-9, 1992.</Citation><Citation idx="15" PMID="21079038">Pertwee RG, Howlett AC, Abood ME, et al.: International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev 62 (4): 588-631, 2010.</Citation><Citation idx="16" PMID="9597153">Felder CC, Glass M: Cannabinoid receptors and their endogenous agonists. Annu Rev Pharmacol Toxicol 38: 179-200, 1998.</Citation><Citation idx="17" PMID="16968947">Pacher P, Bátkai S, Kunos G: The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58 (3): 389-462, 2006.</Citation><Citation idx="18" PMID="23707385">Howard P, Twycross R, Shuster J, et al.: Cannabinoids. J Pain Symptom Manage 46 (1): 142-9, 2013.</Citation><Citation idx="19">Nabiximols. Bethesda, MD:  National Center for Biotechnology Information, 2009. <ExternalRef xref="https://pubchem.ncbi.nlm.nih.gov/compound/Nabiximols">Available online</ExternalRef>. Last accessed June 2, 2021.</Citation></ReferenceSection></SummarySection><SummarySection id="_7"><Title>Laboratory/Animal/Preclinical Studies</Title><Para id="_8"><GlossaryTermRef href="CDR0000716077" dictionary="Cancer.gov" audience="Patient">Cannabinoids</GlossaryTermRef> are a group of 21-carbon–containing terpenophenolic <GlossaryTermRef href="CDR0000422394" dictionary="Cancer.gov" audience="Patient">compounds</GlossaryTermRef> produced uniquely by <ScientificName><GlossaryTermRef href="CDR0000716285" dictionary="Cancer.gov" audience="Patient">Cannabis</GlossaryTermRef></ScientificName> species (e.g., <ScientificName>Cannabis sativa</ScientificName> L.).<Reference refidx="1"/><Reference refidx="2"/>  These plant-derived compounds may be referred to as phytocannabinoids.  Although delta-9-tetrahydrocannabinol (THC) is the primary psychoactive ingredient, other known compounds with biological activity are cannabinol, cannabidiol (CBD), cannabichromene, cannabigerol, tetrahydrocannabivarin, and delta-8-THC. CBD, in particular, is thought to have <GlossaryTermRef href="CDR0000390271" dictionary="Cancer.gov" audience="Patient">significant</GlossaryTermRef> <GlossaryTermRef href="CDR0000045590" dictionary="Cancer.gov" audience="Patient">analgesic</GlossaryTermRef>, <GlossaryTermRef href="CDR0000044187" dictionary="Cancer.gov" audience="Patient">anti-inflammatory</GlossaryTermRef>, and <GlossaryTermRef href="CDR0000044645" dictionary="Cancer.gov" audience="Patient">anxiolytic</GlossaryTermRef> activity without the psychoactive effect (high) of delta-9-THC.</Para><SummarySection id="_26"><Title>Antitumor Effects</Title><Para id="_27">One study in mice and rats suggested that cannabinoids may have a protective effect against the development of certain types of <GlossaryTermRef href="CDR0000046634" dictionary="Cancer.gov" audience="Patient">tumors</GlossaryTermRef>.<Reference refidx="3"/> During this 2-year study, groups of mice and rats were given various <GlossaryTermRef href="CDR0000044664" dictionary="Cancer.gov" audience="Patient">doses</GlossaryTermRef> of THC by <GlossaryTermRef href="CDR0000729771" dictionary="Cancer.gov" audience="Patient">gavage</GlossaryTermRef>.  A dose-related decrease in the <GlossaryTermRef href="CDR0000046145" dictionary="Cancer.gov" audience="Patient">incidence</GlossaryTermRef> of <GlossaryTermRef href="CDR0000045709" dictionary="Cancer.gov" audience="Patient">hepatic</GlossaryTermRef> <GlossaryTermRef href="CDR0000046217" dictionary="Cancer.gov" audience="Patient">adenoma</GlossaryTermRef> tumors and <GlossaryTermRef href="CDR0000046363" dictionary="Cancer.gov" audience="Patient">hepatocellular carcinoma</GlossaryTermRef> (HCC) was observed in the mice.  Decreased incidences of <GlossaryTermRef href="CDR0000046079" dictionary="Cancer.gov" audience="Patient">benign tumors</GlossaryTermRef> (<GlossaryTermRef href="CDR0000045844" dictionary="Cancer.gov" audience="Patient">polyps</GlossaryTermRef> and adenomas) in other <GlossaryTermRef href="CDR0000257523" dictionary="Cancer.gov" audience="Patient">organs</GlossaryTermRef> (<GlossaryTermRef href="CDR0000415575" dictionary="Cancer.gov" audience="Patient">mammary gland</GlossaryTermRef>, <GlossaryTermRef href="CDR0000046645" dictionary="Cancer.gov" audience="Patient">uterus</GlossaryTermRef>, <GlossaryTermRef href="CDR0000046229" dictionary="Cancer.gov" audience="Patient">pituitary</GlossaryTermRef>, <GlossaryTermRef href="CDR0000367406" dictionary="Cancer.gov" audience="Patient">testis</GlossaryTermRef>, and <GlossaryTermRef href="CDR0000046254" dictionary="Cancer.gov" audience="Patient">pancreas</GlossaryTermRef>) were also noted in the rats.  In another study, delta-9-THC, delta-8-THC, and cannabinol were found to inhibit the growth of Lewis <GlossaryTermRef href="CDR0000270740" dictionary="Cancer.gov" audience="Patient">lung</GlossaryTermRef> <GlossaryTermRef href="CDR0000046216" dictionary="Cancer.gov" audience="Patient">adenocarcinoma</GlossaryTermRef> <GlossaryTermRef href="CDR0000046476" dictionary="Cancer.gov" audience="Patient">cells</GlossaryTermRef> <Emphasis><GlossaryTermRef href="CDR0000045733" dictionary="Cancer.gov" audience="Patient">in vitro</GlossaryTermRef></Emphasis> and <Emphasis><GlossaryTermRef href="CDR0000046352" dictionary="Cancer.gov" audience="Patient">in vivo</GlossaryTermRef></Emphasis>.<Reference refidx="4"/>  In addition, other tumors have been shown to be sensitive to cannabinoid-induced growth inhibition.<Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/></Para><Para id="_28">Cannabinoids may cause  <GlossaryTermRef href="CDR0000446109" dictionary="Cancer.gov" audience="Patient">antitumor</GlossaryTermRef> effects by various mechanisms, including <GlossaryTermRef href="CDR0000045736" dictionary="Cancer.gov" audience="Patient">induction</GlossaryTermRef> of <GlossaryTermRef href="CDR0000046476" dictionary="Cancer.gov" audience="Patient">cell</GlossaryTermRef> death, inhibition of cell growth, and inhibition of tumor <GlossaryTermRef href="CDR0000046529" dictionary="Cancer.gov" audience="Patient">angiogenesis</GlossaryTermRef> invasion and <GlossaryTermRef href="CDR0000046710" dictionary="Cancer.gov" audience="Patient">metastasis</GlossaryTermRef>.<Reference refidx="9"/><Reference refidx="10"/><Reference refidx="11"/><Reference refidx="12"/> Two reviews summarize the molecular mechanisms of action of cannabinoids as antitumor agents.<Reference refidx="13"/><Reference refidx="14"/> Cannabinoids appear to kill tumor cells but do not affect their nontransformed counterparts and may even protect them from cell death.  For example, these compounds have been shown to induce <GlossaryTermRef href="CDR0000046524" dictionary="Cancer.gov" audience="Patient">apoptosis</GlossaryTermRef> in <GlossaryTermRef href="CDR0000045700" dictionary="Cancer.gov" audience="Patient">glioma</GlossaryTermRef> cells in <GlossaryTermRef href="CDR0000476357" dictionary="Cancer.gov" audience="Patient">culture</GlossaryTermRef> and induce <GlossaryTermRef href="CDR0000046039" dictionary="Cancer.gov" audience="Patient">regression</GlossaryTermRef> of glioma tumors in mice and rats, while they protect normal glial cells of astroglial and oligodendroglial lineages from apoptosis mediated by the CB1 <GlossaryTermRef href="CDR0000044958" dictionary="Cancer.gov" audience="Patient">receptor</GlossaryTermRef>.<Reference refidx="9"/></Para><Para id="_143">The effects of delta-9-THC and a <GlossaryTermRef href="CDR0000462950" dictionary="Cancer.gov" audience="Patient">synthetic</GlossaryTermRef> <GlossaryTermRef href="CDR0000046054" dictionary="Cancer.gov" audience="Patient">agonist</GlossaryTermRef> of the CB2 receptor were investigated in HCC.<Reference refidx="15"/> Both agents reduced the viability of HCC cells <Emphasis>in vitro</Emphasis> and demonstrated antitumor effects in HCC <GlossaryTermRef href="CDR0000045914" dictionary="Cancer.gov" audience="Patient">subcutaneous</GlossaryTermRef> <GlossaryTermRef href="CDR0000044095" dictionary="Cancer.gov" audience="Patient">xenografts</GlossaryTermRef> in nude mice. The investigations documented that the anti-HCC effects are mediated by way of the CB2 receptor. Similar to findings in glioma cells, the cannabinoids were shown to trigger cell death through stimulation of an <GlossaryTermRef href="CDR0000763770" dictionary="Cancer.gov" audience="Patient">endoplasmic reticulum</GlossaryTermRef> stress pathway that activates <GlossaryTermRef href="CDR0000561319" dictionary="Cancer.gov" audience="Patient">autophagy</GlossaryTermRef> and promotes apoptosis. Other investigations have confirmed that CB1 and CB2 receptors may be potential targets in <GlossaryTermRef href="CDR0000045323" dictionary="Cancer.gov" audience="Patient">non-small cell lung</GlossaryTermRef> <GlossaryTermRef href="CDR0000045963" dictionary="Cancer.gov" audience="Patient">carcinoma</GlossaryTermRef> <Reference refidx="16"/> and <GlossaryTermRef href="CDR0000444971" dictionary="Cancer.gov" audience="Patient">breast cancer</GlossaryTermRef>.<Reference refidx="17"/></Para><Para id="_152">An <Emphasis>in vitro</Emphasis> study of the effect of CBD on <GlossaryTermRef href="CDR0000407582" dictionary="Cancer.gov" audience="Patient">programmed cell death</GlossaryTermRef> in breast cancer <GlossaryTermRef href="CDR0000044016" dictionary="Cancer.gov" audience="Patient">cell lines</GlossaryTermRef> found  that CBD induced programmed cell death, independent  of the CB1, CB2, or vanilloid receptors.  CBD inhibited the survival of both <GlossaryTermRef href="CDR0000045270" dictionary="Cancer.gov" audience="Patient">estrogen receptor–positive</GlossaryTermRef> and <GlossaryTermRef href="CDR0000045272" dictionary="Cancer.gov" audience="Patient">estrogen receptor–negative</GlossaryTermRef> breast cancer cell lines, inducing apoptosis in a concentration-dependent manner while having little effect on nontumorigenic <GlossaryTermRef href="CDR0000044560" dictionary="Cancer.gov" audience="Patient">mammary</GlossaryTermRef> cells.<Reference refidx="18"/> Other studies have also shown the antitumor effect of cannabinoids (i.e., CBD and THC) in preclinical models of breast cancer.<Reference refidx="19"/><Reference refidx="20"/></Para><Para id="_154">CBD has also been demonstrated to exert a <GlossaryTermRef href="CDR0000045487" dictionary="Cancer.gov" audience="Patient">chemopreventive</GlossaryTermRef> effect in a <GlossaryTermRef href="CDR0000561606" dictionary="Cancer.gov" audience="Patient">mouse model</GlossaryTermRef> of <GlossaryTermRef href="CDR0000044237" dictionary="Cancer.gov" audience="Patient">colon cancer</GlossaryTermRef>.<Reference refidx="21"/> In this <GlossaryTermRef href="CDR0000044758" dictionary="Cancer.gov" audience="Patient">experimental</GlossaryTermRef> system, <GlossaryTermRef href="CDR0000367457" dictionary="Cancer.gov" audience="Patient">azoxymethane</GlossaryTermRef> increased <GlossaryTermRef href="CDR0000045846" dictionary="Cancer.gov" audience="Patient">premalignant</GlossaryTermRef> and malignant <GlossaryTermRef href="CDR0000046324" dictionary="Cancer.gov" audience="Patient">lesions</GlossaryTermRef> in the mouse colon. Animals treated with azoxymethane and CBD concurrently were protected from developing premalignant and malignant lesions. In <Emphasis>in vitro</Emphasis> experiments involving <GlossaryTermRef href="CDR0000444983" dictionary="Cancer.gov" audience="Patient">colorectal cancer</GlossaryTermRef> cell lines, the investigators found that CBD protected <GlossaryTermRef href="CDR0000045671" dictionary="Genetics" audience="Health professional">DNA</GlossaryTermRef> from oxidative damage, increased endocannabinoid levels, and reduced <GlossaryTermRef href="CDR0000046479" dictionary="Cancer.gov" audience="Patient">cell proliferation</GlossaryTermRef>. In a subsequent  study, the investigators found that the antiproliferative effect of CBD was counteracted by selective CB1 but not CB2 receptor <GlossaryTermRef href="CDR0000350250" dictionary="Cancer.gov" audience="Patient">antagonists</GlossaryTermRef>, suggesting an involvement of CB1 receptors.<Reference refidx="22"/></Para><Para id="_155">Another investigation into the antitumor effects of CBD examined the role of intercellular adhesion molecule-1 (ICAM-1).<Reference refidx="12"/>  ICAM-1 expression in tumor cells has been reported to be negatively correlated with cancer <GlossaryTermRef href="CDR0000046710" dictionary="Cancer.gov" audience="Patient">metastasis.</GlossaryTermRef> In <GlossaryTermRef href="CDR0000445043" dictionary="Cancer.gov" audience="Patient">lung cancer</GlossaryTermRef> cell lines, CBD upregulated ICAM-1, leading to decreased cancer cell invasiveness.</Para><Para id="_29">In an <Emphasis>in vivo</Emphasis> model using severe combined immunodeficient mice, subcutaneous tumors were generated by inoculating the animals with cells from human non-small cell lung carcinoma cell lines.<Reference refidx="23"/> Tumor growth was inhibited by 60% in THC-treated mice compared with vehicle-treated control mice.  Tumor specimens revealed that THC had <GlossaryTermRef href="CDR0000044186" dictionary="Cancer.gov" audience="Patient">antiangiogenic</GlossaryTermRef> and antiproliferative effects. However, research with <GlossaryTermRef href="CDR0000044835" dictionary="Cancer.gov" audience="Patient">immunocompetent</GlossaryTermRef> murine <GlossaryTermRef href="CDR0000044091" dictionary="Cancer.gov" audience="Patient">tumor models</GlossaryTermRef> has demonstrated <GlossaryTermRef href="CDR0000045727" dictionary="Cancer.gov" audience="Patient">immunosuppression</GlossaryTermRef> and enhanced tumor growth in mice treated with THC.<Reference refidx="24"/><Reference refidx="25"/></Para><Para id="_30">In addition, both plant-derived and <GlossaryTermRef href="CDR0000044026" dictionary="Cancer.gov" audience="Patient">endogenous</GlossaryTermRef> cannabinoids have been studied for anti-<GlossaryTermRef href="CDR0000373080" dictionary="Cancer.gov" audience="Patient">inflammatory</GlossaryTermRef> effects.  A mouse study demonstrated that  endogenous cannabinoid system signaling is likely to provide intrinsic protection against colonic <GlossaryTermRef href="CDR0000044042" dictionary="Cancer.gov" audience="Patient">inflammation</GlossaryTermRef>.<Reference refidx="26"/> As a result, a <GlossaryTermRef href="CDR0000044209" dictionary="Cancer.gov" audience="Patient">hypothesis</GlossaryTermRef> that phytocannabinoids and endocannabinoids may be useful in the risk reduction and treatment of <GlossaryTermRef href="CDR0000444983" dictionary="Cancer.gov" audience="Patient">colorectal cancer</GlossaryTermRef> has been developed.<Reference refidx="27"/><Reference refidx="28"/><Reference refidx="29"/><Reference refidx="30"/></Para><Para id="_188">CBD may also enhance uptake of <GlossaryTermRef href="CDR0000044020" dictionary="Cancer.gov" audience="Patient">cytotoxic</GlossaryTermRef> drugs into malignant cells. Activation of transient receptor potential vanilloid type 2 (TRPV2) has been shown to inhibit proliferation of human <GlossaryTermRef href="CDR0000045699" dictionary="Cancer.gov" audience="Patient">glioblastoma multiforme</GlossaryTermRef> cells and overcome resistance to the <GlossaryTermRef href="CDR0000045214" dictionary="Cancer.gov" audience="Patient">chemotherapy</GlossaryTermRef> agent <GlossaryTermRef href="CDR0000045976" dictionary="Cancer.gov" audience="Patient">carmustine.</GlossaryTermRef><Reference refidx="31"/> One study showed that coadministration of THC and CBD over single-agent usage had greater antiproliferative activity in an <Emphasis>in vitro</Emphasis> study with multiple human glioblastoma multiforme cell lines.<Reference refidx="32"/> In an <Emphasis>in vitro</Emphasis> model, CBD increased TRPV2 activation and increased uptake of cytotoxic drugs,  leading to apoptosis of glioma cells without affecting normal human <GlossaryTermRef href="CDR0000269436" dictionary="Cancer.gov" audience="Patient">astrocytes</GlossaryTermRef>.  This suggests that coadministration of CBD with cytotoxic agents may increase drug uptake and potentiate cell death in human glioma cells. Also, CBD together with THC may enhance the antitumor activity of classic chemotherapeutic drugs such as <GlossaryTermRef href="CDR0000045387" dictionary="Cancer.gov" audience="Patient">temozolomide</GlossaryTermRef> in some mouse models of cancer.<Reference refidx="13"/><Reference refidx="33"/> A <GlossaryTermRef href="CDR0000691484" dictionary="Cancer.gov" audience="Patient">meta-analysis</GlossaryTermRef> of 34 <Emphasis>in vitro</Emphasis> and <Emphasis>in vivo</Emphasis> studies of cannabinoids in glioma reported that all but one study confirmed that cannabinoids selectively kill tumor cells.<Reference refidx="34"/></Para></SummarySection><SummarySection id="_227"><Title>Antiemetic Effects</Title><Para id="_228">Preclinical research suggests that emetic circuitry is tonically controlled by endocannabinoids. The <GlossaryTermRef href="CDR0000046084" dictionary="Cancer.gov" audience="Patient">antiemetic</GlossaryTermRef> action of cannabinoids is believed to be mediated via interaction with the <GlossaryTermRef href="CDR0000335512" dictionary="Cancer.gov" audience="Patient">5-hydroxytryptamine</GlossaryTermRef> 3 (5-HT3) receptor. CB1 receptors and 5-HT3 receptors are colocalized on gamma-aminobutyric acid (GABA)-ergic neurons, where they have opposite effects on GABA release.<Reference refidx="35"/>  There also may be direct inhibition of 5-HT3 gated <GlossaryTermRef href="CDR0000643017" dictionary="Cancer.gov" audience="Patient">ion</GlossaryTermRef> currents through non–CB1 receptor pathways. CB1 receptor antagonists have been shown to elicit <GlossaryTermRef href="CDR0000256560" dictionary="Cancer.gov" audience="Patient">emesis</GlossaryTermRef> in the least shrew that is reversed by cannabinoid agonists.<Reference refidx="36"/>  The involvement of CB1 receptor in emesis prevention has been shown by the ability of CB1 antagonists to reverse the effects of THC and other <GlossaryTermRef href="CDR0000462950" dictionary="Cancer.gov" audience="Patient">synthetic</GlossaryTermRef> cannabinoid CB1 agonists in suppressing vomiting caused by <GlossaryTermRef href="CDR0000045230" dictionary="Cancer.gov" audience="Patient">cisplatin</GlossaryTermRef> in the house musk shrew and <GlossaryTermRef href="CDR0000476347" dictionary="Cancer.gov" audience="Patient">lithium</GlossaryTermRef> chloride in the least shrew.  In the latter model, CBD was also shown to be efficacious.<Reference refidx="37"/><Reference refidx="38"/></Para></SummarySection><SummarySection id="_32"><Title>Appetite Stimulation</Title><Para id="_33">Many <GlossaryTermRef href="CDR0000454774" dictionary="Cancer.gov" audience="Patient">animal studies</GlossaryTermRef> have previously demonstrated that delta-9-THC and other cannabinoids have a stimulatory effect on <GlossaryTermRef href="CDR0000454699" dictionary="Cancer.gov" audience="Patient">appetite</GlossaryTermRef> and increase food intake.  It is believed that the endogenous cannabinoid system may serve as a regulator of feeding behavior.  The endogenous cannabinoid anandamide potently enhances appetite in mice.<Reference refidx="39"/>  Moreover, CB1 <GlossaryTermRef href="CDR0000044958" dictionary="Cancer.gov" audience="Patient">receptors</GlossaryTermRef> in the <GlossaryTermRef href="CDR0000046359" dictionary="Cancer.gov" audience="Patient">hypothalamus</GlossaryTermRef> may be involved in the motivational or reward aspects of eating.<Reference refidx="40"/></Para></SummarySection><SummarySection id="_34"><Title>Analgesia</Title><Para id="_35">Understanding  the mechanism of cannabinoid-induced <GlossaryTermRef href="CDR0000449929" dictionary="Cancer.gov" audience="Patient">analgesia</GlossaryTermRef> has been increased through the study of cannabinoid receptors, endocannabinoids, and synthetic agonists and antagonists. Cannabinoids produce analgesia through supraspinal, spinal, and peripheral modes of action, acting on both ascending and descending pain pathways.<Reference refidx="41"/> The CB1 receptor is found in both the <GlossaryTermRef href="CDR0000046481" dictionary="Cancer.gov" audience="Patient">central nervous system</GlossaryTermRef> (CNS) and in peripheral <GlossaryTermRef href="CDR0000373935" dictionary="Cancer.gov" audience="Patient">nerve</GlossaryTermRef> terminals.  Similar to <GlossaryTermRef href="CDR0000045054" dictionary="Cancer.gov" audience="Patient">opioid</GlossaryTermRef> receptors, increased levels of the CB1 receptor are found in regions of the brain that regulate nociceptive processing.<Reference refidx="42"/>  CB2 receptors, located predominantly in peripheral <GlossaryTermRef href="CDR0000046683" dictionary="Cancer.gov" audience="Patient">tissue</GlossaryTermRef>, exist at very low levels in the CNS.  With the development of receptor-specific antagonists, additional information about the roles of the receptors and endogenous cannabinoids in the modulation of pain has been obtained.<Reference refidx="43"/><Reference refidx="44"/></Para><Para id="_36">Cannabinoids may also contribute to pain modulation through an anti-inflammatory mechanism; a CB2 effect with cannabinoids acting  on <GlossaryTermRef href="CDR0000044845" dictionary="Cancer.gov" audience="Patient">mast cell</GlossaryTermRef> receptors to attenuate the release of inflammatory agents, such as <GlossaryTermRef href="CDR0000657848" dictionary="Cancer.gov" audience="Patient">histamine</GlossaryTermRef> and <GlossaryTermRef href="CDR0000335511" dictionary="Cancer.gov" audience="Patient">serotonin</GlossaryTermRef>, and on keratinocytes to enhance the release of analgesic <GlossaryTermRef href="CDR0000045054" dictionary="Cancer.gov" audience="Patient">opioids</GlossaryTermRef> has been described.<Reference refidx="45"/><Reference refidx="46"/><Reference refidx="47"/> One study reported that the efficacy of synthetic CB1- and CB2-receptor agonists were comparable with the efficacy of morphine in a murine model of tumor pain.<Reference refidx="48"/></Para><Para id="_229">Cannabinoids have been shown to prevent chemotherapy-induced <GlossaryTermRef href="CDR0000046041" dictionary="Cancer.gov" audience="Patient">neuropathy</GlossaryTermRef> in animal models exposed to <GlossaryTermRef href="CDR0000045258" dictionary="Cancer.gov" audience="Patient">paclitaxel</GlossaryTermRef>, <GlossaryTermRef href="CDR0000615324" dictionary="Cancer.gov" audience="Patient">vincristine</GlossaryTermRef>, or cisplatin.<Reference refidx="49"/><Reference refidx="50"/><Reference refidx="51"/></Para></SummarySection><SummarySection id="_230"><Title>Anxiety and Sleep</Title><Para id="_231">The endocannabinoid system is believed to be centrally involved in the regulation of mood and the extinction of aversive memories. Animal studies have shown CBD to have anxiolytic properties. It was shown in rats that these anxiolytic properties are mediated through unknown mechanisms.<Reference refidx="52"/>   Anxiolytic effects of CBD have been shown in several animal models.<Reference refidx="53"/><Reference refidx="54"/></Para><Para id="_232">The endocannabinoid system has also been shown to play a key role in the modulation of the sleep-waking cycle in rats.<Reference refidx="55"/><Reference refidx="56"/></Para></SummarySection><ReferenceSection><Citation idx="1" PMID="8972919">Adams IB, Martin BR: Cannabis: pharmacology and toxicology in animals and humans. Addiction 91 (11): 1585-614, 1996.</Citation><Citation idx="2">Grotenhermen F, Russo E, eds.: Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential. The Haworth Press, 2002.</Citation><Citation idx="3" PMID="12594529">National Toxicology Program: NTP toxicology and carcinogenesis studies of 1-trans-delta(9)-tetrahydrocannabinol (CAS No. 1972-08-3) in F344 rats and B6C3F1 mice (gavage studies). Natl Toxicol Program Tech Rep Ser 446: 1-317, 1996.</Citation><Citation idx="4" PMID="16501583">Bifulco M, Laezza C, Pisanti S, et al.: Cannabinoids and cancer: pros and cons of an antitumour strategy. Br J Pharmacol 148 (2): 123-35, 2006.</Citation><Citation idx="5" PMID="11479216">Sánchez C, de Ceballos ML, Gomez del Pulgar T, et al.: Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res 61 (15): 5784-9, 2001.</Citation><Citation idx="6" PMID="12091357">McKallip RJ, Lombard C, Fisher M, et al.: Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 100 (2): 627-34, 2002.</Citation><Citation idx="7" PMID="12511587">Casanova ML, Blázquez C, Martínez-Palacio J, et al.: Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest 111 (1): 43-50, 2003.</Citation><Citation idx="8" PMID="15313899">Blázquez C, González-Feria L, Alvarez L, et al.: Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res 64 (16): 5617-23, 2004.</Citation><Citation idx="9" PMID="14570037">Guzmán M: Cannabinoids: potential anticancer agents. Nat Rev Cancer 3 (10): 745-55, 2003.</Citation><Citation idx="10" PMID="12514108">Blázquez C, Casanova ML, Planas A, et al.: Inhibition of tumor angiogenesis by cannabinoids. FASEB J 17 (3): 529-31, 2003.</Citation><Citation idx="11" PMID="15700028">Vaccani A, Massi P, Colombo A, et al.: Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. Br J Pharmacol 144 (8): 1032-6, 2005.</Citation><Citation idx="12" PMID="22198381">Ramer R, Bublitz K, Freimuth N, et al.: Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1. FASEB J 26 (4): 1535-48, 2012.</Citation><Citation idx="13" PMID="22555283">Velasco G, Sánchez C, Guzmán M: Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer 12 (6): 436-44, 2012.</Citation><Citation idx="14" PMID="24039449">Cridge BJ, Rosengren RJ: Critical appraisal of the potential use of cannabinoids in cancer management. Cancer Manag Res 5: 301-13, 2013.</Citation><Citation idx="15" PMID="21475304">Vara D, Salazar M, Olea-Herrero N, et al.: Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy. Cell Death Differ 18 (7): 1099-111, 2011.</Citation><Citation idx="16" PMID="21097714">Preet A, Qamri Z, Nasser MW, et al.: Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer growth and metastasis. Cancer Prev Res (Phila) 4 (1): 65-75, 2011.</Citation><Citation idx="17" PMID="21915267">Nasser MW, Qamri Z, Deol YS, et al.: Crosstalk between chemokine receptor CXCR4 and cannabinoid receptor CB2 in modulating breast cancer growth and invasion. PLoS One 6 (9): e23901, 2011.</Citation><Citation idx="18" PMID="21566064">Shrivastava A, Kuzontkoski PM, Groopman JE, et al.: Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. Mol Cancer Ther 10 (7): 1161-72, 2011.</Citation><Citation idx="19" PMID="20649976">Caffarel MM, Andradas C, Mira E, et al.: Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Mol Cancer 9: 196, 2010.</Citation><Citation idx="20" PMID="20859676">McAllister SD, Murase R, Christian RT, et al.: Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Res Treat 129 (1): 37-47, 2011.</Citation><Citation idx="21" PMID="22231745">Aviello G, Romano B, Borrelli F, et al.: Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer. J Mol Med (Berl) 90 (8): 925-34, 2012.</Citation><Citation idx="22" PMID="24373545">Romano B, Borrelli F, Pagano E, et al.: Inhibition of colon carcinogenesis by a standardized Cannabis sativa extract with high content of cannabidiol. Phytomedicine 21 (5): 631-9, 2014.</Citation><Citation idx="23" PMID="17621270">Preet A, Ganju RK, Groopman JE: Delta9-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. Oncogene 27 (3): 339-46, 2008.</Citation><Citation idx="24" PMID="10861074">Zhu LX, Sharma S, Stolina M, et al.: Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J Immunol 165 (1): 373-80, 2000.</Citation><Citation idx="25" PMID="15749859">McKallip RJ, Nagarkatti M, Nagarkatti PS: Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. J Immunol 174 (6): 3281-9, 2005.</Citation><Citation idx="26" PMID="15085199">Massa F, Marsicano G, Hermann H, et al.: The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 113 (8): 1202-9, 2004.</Citation><Citation idx="27" PMID="16042581">Patsos HA, Hicks DJ, Greenhough A, et al.: Cannabinoids and cancer: potential for colorectal cancer therapy. Biochem Soc Trans 33 (Pt 4): 712-4, 2005.</Citation><Citation idx="28" PMID="20925645">Liu WM, Fowler DW, Dalgleish AG: Cannabis-derived substances in cancer therapy--an emerging anti-inflammatory role for the cannabinoids. Curr Clin Pharmacol 5 (4): 281-7, 2010.</Citation><Citation idx="29" PMID="21244344">Malfitano AM, Ciaglia E, Gangemi G, et al.: Update on the endocannabinoid system as an anticancer target. Expert Opin Ther Targets 15 (3): 297-308, 2011.</Citation><Citation idx="30" PMID="18199524">Sarfaraz S, Adhami VM, Syed DN, et al.: Cannabinoids for cancer treatment: progress and promise. Cancer Res 68 (2): 339-42, 2008.</Citation><Citation idx="31" PMID="23079154">Nabissi M, Morelli MB, Santoni M, et al.: Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents. Carcinogenesis 34 (1): 48-57, 2013.</Citation><Citation idx="32" PMID="20053780">Marcu JP, Christian RT, Lau D, et al.: Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival. Mol Cancer Ther 9 (1): 180-9, 2010.</Citation><Citation idx="33" PMID="21220494">Torres S, Lorente M, Rodríguez-Fornés F, et al.: A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther 10 (1): 90-103, 2011.</Citation><Citation idx="34" PMID="24142199">Rocha FC, Dos Santos Júnior JG, Stefano SC, et al.: Systematic review of the literature on clinical and experimental trials on the antitumor effects of cannabinoids in gliomas. J Neurooncol 116 (1): 11-24, 2014.</Citation><Citation idx="35" PMID="16968947">Pacher P, Bátkai S, Kunos G: The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58 (3): 389-462, 2006.</Citation><Citation idx="36" PMID="11120402">Darmani NA: Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A. Neuropsychopharmacology 24 (2): 198-203, 2001.</Citation><Citation idx="37" PMID="11420092">Darmani NA: Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew. Pharmacol Biochem Behav 69 (1-2): 239-49, 2001 May-Jun.</Citation><Citation idx="38" PMID="13680081">Parker LA, Kwiatkowska M, Burton P, et al.: Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew). Psychopharmacology (Berl) 171 (2): 156-61, 2004.</Citation><Citation idx="39" PMID="16570101">Mechoulam R, Berry EM, Avraham Y, et al.: Endocannabinoids, feeding and suckling--from our perspective. Int J Obes (Lond) 30 (Suppl 1): S24-8, 2006.</Citation><Citation idx="40" PMID="15792943">Fride E, Bregman T, Kirkham TC: Endocannabinoids and food intake: newborn suckling and appetite regulation in adulthood. Exp Biol Med (Maywood) 230 (4): 225-34, 2005.</Citation><Citation idx="41" PMID="12849183">Baker D, Pryce G, Giovannoni G, et al.: The therapeutic potential of cannabis. Lancet Neurol 2 (5): 291-8, 2003.</Citation><Citation idx="42" PMID="10462067">Walker JM, Hohmann AG, Martin WJ, et al.: The neurobiology of cannabinoid analgesia. Life Sci 65 (6-7): 665-73, 1999.</Citation><Citation idx="43" PMID="9759727">Meng ID, Manning BH, Martin WJ, et al.: An analgesia circuit activated by cannabinoids. Nature 395 (6700): 381-3, 1998.</Citation><Citation idx="44" PMID="10518599">Walker JM, Huang SM, Strangman NM, et al.: Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci U S A 96 (21): 12198-203, 1999.</Citation><Citation idx="45" PMID="7724569">Facci L, Dal Toso R, Romanello S, et al.: Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci U S A 92 (8): 3376-80, 1995.</Citation><Citation idx="46" PMID="15705714">Ibrahim MM, Porreca F, Lai J, et al.: CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci U S A 102 (8): 3093-8, 2005.</Citation><Citation idx="47" PMID="9539680">Richardson JD, Kilo S, Hargreaves KM: Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 75 (1): 111-9, 1998.</Citation><Citation idx="48" PMID="21610490">Khasabova IA, Gielissen J, Chandiramani A, et al.: CB1 and CB2 receptor agonists promote analgesia through synergy in a murine model of tumor pain. Behav Pharmacol 22 (5-6): 607-16, 2011.</Citation><Citation idx="49" PMID="24117398">Ward SJ, McAllister SD, Kawamura R, et al.: Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy. Br J Pharmacol 171 (3): 636-45, 2014.</Citation><Citation idx="50" PMID="17572696">Rahn EJ, Makriyannis A, Hohmann AG: Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. Br J Pharmacol 152 (5): 765-77, 2007.</Citation><Citation idx="51" PMID="22593077">Khasabova IA, Khasabov S, Paz J, et al.: Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy. J Neurosci 32 (20): 7091-101, 2012.</Citation><Citation idx="52" PMID="18446323">Campos AC, Guimarães FS: Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharmacology (Berl) 199 (2): 223-30, 2008.</Citation><Citation idx="53" PMID="20512271">Crippa JA, Zuardi AW, Hallak JE: [Therapeutical use of the cannabinoids in psychiatry]. Rev Bras Psiquiatr 32 (Suppl 1): S56-66, 2010.</Citation><Citation idx="54" PMID="1969666">Guimarães FS, Chiaretti TM, Graeff FG, et al.: Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology (Berl) 100 (4): 558-9, 1990.</Citation><Citation idx="55" PMID="23584096">Méndez-Díaz M, Caynas-Rojas S, Arteaga Santacruz V, et al.: Entopeduncular nucleus endocannabinoid system modulates sleep-waking cycle and mood in rats. Pharmacol Biochem Behav 107: 29-35, 2013.</Citation><Citation idx="56" PMID="24520411">Pava MJ, den Hartog CR, Blanco-Centurion C, et al.: Endocannabinoid modulation of cortical up-states and NREM sleep. PLoS One 9 (2): e88672, 2014.</Citation></ReferenceSection></SummarySection><SummarySection id="_9"><Title>Human/Clinical Studies</Title><SummarySection id="_37"><Title><ScientificName>Cannabis</ScientificName> Pharmacology</Title><Para id="_38">  When <GlossaryTermRef href="CDR0000044068" dictionary="Cancer.gov" audience="Patient">oral</GlossaryTermRef> <ScientificName><GlossaryTermRef href="CDR0000716285" dictionary="Cancer.gov" audience="Patient">Cannabis</GlossaryTermRef></ScientificName> is <GlossaryTermRef href="CDR0000044100" dictionary="Cancer.gov" audience="Patient">ingested</GlossaryTermRef>, there is a low (6%–20%) and variable oral <GlossaryTermRef href="CDR0000044225" dictionary="Cancer.gov" audience="Patient">bioavailability</GlossaryTermRef>.<Reference refidx="1"/><Reference refidx="2"/>  Peak <GlossaryTermRef href="CDR0000045839" dictionary="Cancer.gov" audience="Patient">plasma</GlossaryTermRef> concentrations of delta-9-tetrahydrocannabinol (THC) occur after 1 to 6 hours and remain elevated with a terminal half-life of 20 to 30 hours.  Taken by mouth,  delta-9-THC is initially metabolized in the <GlossaryTermRef href="CDR0000046312" dictionary="Cancer.gov" audience="Patient">liver</GlossaryTermRef> to 11-OH-THC, a potent psychoactive <GlossaryTermRef href="CDR0000462687" dictionary="Cancer.gov" audience="Patient">metabolite</GlossaryTermRef>.  <GlossaryTermRef href="CDR0000044600" dictionary="Cancer.gov" audience="Patient">Inhaled</GlossaryTermRef> <GlossaryTermRef href="CDR0000716077" dictionary="Cancer.gov" audience="Patient">cannabinoids</GlossaryTermRef> are rapidly absorbed into the bloodstream with a peak <GlossaryTermRef href="CDR0000683342" dictionary="Cancer.gov" audience="Patient">concentration</GlossaryTermRef> in 2 to 10 minutes, declining rapidly for a period of 30 minutes and with less generation of the psychoactive 11-OH metabolite.</Para><Para id="_39">Cannabinoids are known to interact with the <GlossaryTermRef href="CDR0000045709" dictionary="Cancer.gov" audience="Patient">hepatic</GlossaryTermRef> <GlossaryTermRef href="CDR0000390266" dictionary="Cancer.gov" audience="Patient">cytochrome P450 enzyme system</GlossaryTermRef>.<Reference refidx="3"/><Reference refidx="4"/> In one study, 24 patients with <GlossaryTermRef href="CDR0000045333" dictionary="Cancer.gov" audience="Patient">cancer</GlossaryTermRef> were treated with <GlossaryTermRef href="CDR0000046682" dictionary="Cancer.gov" audience="Patient">intravenous</GlossaryTermRef> <GlossaryTermRef href="CDR0000635811" dictionary="Cancer.gov" audience="Patient">irinotecan</GlossaryTermRef> (600 <GlossaryTermRef href="CDR0000044213" dictionary="Cancer.gov" audience="Patient">mg</GlossaryTermRef>, n = 12) or <GlossaryTermRef href="CDR0000045382" dictionary="Cancer.gov" audience="Patient">docetaxel</GlossaryTermRef> (180 mg, n = 12), followed 3 weeks later by the same <GlossaryTermRef href="CDR0000348921" dictionary="Cancer.gov" audience="Patient">drugs</GlossaryTermRef> <GlossaryTermRef href="CDR0000635464" dictionary="Cancer.gov" audience="Patient">concomitant</GlossaryTermRef> with medicinal <ScientificName>Cannabis</ScientificName> taken in the form of an <GlossaryTermRef href="CDR0000463714" dictionary="Cancer.gov" audience="Patient">herbal</GlossaryTermRef> tea for 15 consecutive days, starting 12 days before the second treatment.<Reference refidx="4"/> The <GlossaryTermRef href="CDR0000478733" dictionary="Cancer.gov" audience="Patient">administration</GlossaryTermRef> of <ScientificName>Cannabis</ScientificName> did not significantly influence exposure to and clearance of irinotecan or docetaxel, although the herbal tea route of administration may not reproduce the effects of inhalation or oral <GlossaryTermRef href="CDR0000044100" dictionary="Cancer.gov" audience="Patient">ingestion</GlossaryTermRef> of fat-<GlossaryTermRef href="CDR0000467861" dictionary="Cancer.gov" audience="Patient">soluble</GlossaryTermRef> cannabinoids.</Para><Para id="_289"> Highly concentrated THC or cannabidiol (CBD) oil <GlossaryTermRef href="CDR0000407760" dictionary="Cancer.gov" audience="Patient">extracts</GlossaryTermRef> are illegally promoted as potential cancer <GlossaryTermRef href="CDR0000318813" dictionary="Cancer.gov" audience="Patient">cures</GlossaryTermRef>.<Reference refidx="5"/> These oils have not been evaluated in any <GlossaryTermRef href="CDR0000045961" dictionary="Cancer.gov" audience="Patient">clinical trials</GlossaryTermRef> for anticancer activity or safety. Because CBD is a potential inhibitor of certain cytochrome P450 <GlossaryTermRef href="CDR0000046081" dictionary="Cancer.gov" audience="Patient">enzymes</GlossaryTermRef>, highly concentrated CBD oils used concurrently with <GlossaryTermRef href="CDR0000044198" dictionary="Cancer.gov" audience="Patient">conventional therapies</GlossaryTermRef> that are metabolized by these enzymes could potentially increase <GlossaryTermRef href="CDR0000445093" dictionary="Cancer.gov" audience="Patient">toxicity</GlossaryTermRef> or decrease the effectiveness of these therapies.<Reference refidx="6"/><Reference refidx="7"/></Para><Para id="_391">Additionally, multiple reliability and quality concerns have been raised about <ScientificName>Cannabis</ScientificName> analytical labs, alleging the inflation of cannabinoids content in different <ScientificName>Cannabis</ScientificName> products. One study showed major inconsistencies in reported THC content because of an insufficient stabilization of sample preparation and testing methods.<Reference refidx="8"/></Para></SummarySection><SummarySection id="_105"><Title>Cancer Risk</Title><Para id="_106">A number of studies have yielded conflicting evidence regarding the risks of various cancers associated with <ScientificName>Cannabis</ScientificName> smoking.</Para><Para id="_112">A pooled analysis of three case-cohort studies of men in northwestern Africa (430 cases and 778 <GlossaryTermRef href="CDR0000044149" dictionary="Cancer.gov" audience="Patient">controls</GlossaryTermRef>) showed a significantly increased risk of <GlossaryTermRef href="CDR0000445043" dictionary="Cancer.gov" audience="Patient">lung cancer</GlossaryTermRef> among <GlossaryTermRef href="CDR0000439432" dictionary="Cancer.gov" audience="Patient">tobacco</GlossaryTermRef> smokers who also inhaled <ScientificName>Cannabis</ScientificName>.<Reference refidx="9"/></Para><Para id="_113">A large, <GlossaryTermRef href="CDR0000286525" dictionary="Cancer.gov" audience="Patient">retrospective cohort study</GlossaryTermRef> of 64,855 men aged 15 to 49 years from the United States found that <ScientificName>Cannabis</ScientificName> use was not associated with tobacco-related cancers and a number of other common <GlossaryTermRef href="CDR0000045771" dictionary="Cancer.gov" audience="Patient">malignancies</GlossaryTermRef>. However, the study did find that, among nonsmokers of tobacco, ever having used <ScientificName>Cannabis</ScientificName> was associated with an increased risk of <GlossaryTermRef href="CDR0000445079" dictionary="Cancer.gov" audience="Patient">prostate cancer</GlossaryTermRef>.<Reference refidx="10"/></Para><Para id="_114"> A population-based <GlossaryTermRef href="CDR0000348989" dictionary="Cancer.gov" audience="Patient">case-control study</GlossaryTermRef> of 611 patients with lung cancer revealed that <GlossaryTermRef href="CDR0000045641" dictionary="Cancer.gov" audience="Patient">chronic</GlossaryTermRef> low <ScientificName>Cannabis</ScientificName> exposure was not associated with an increased risk of lung cancer or other upper <GlossaryTermRef href="CDR0000044811" dictionary="Cancer.gov" audience="Patient">aerodigestive tract</GlossaryTermRef> cancers. The study also found no positive associations with any cancer type (<GlossaryTermRef href="CDR0000044068" dictionary="Cancer.gov" audience="Patient">oral</GlossaryTermRef>, <GlossaryTermRef href="CDR0000046061" dictionary="Cancer.gov" audience="Patient">pharyngeal</GlossaryTermRef>, <GlossaryTermRef href="CDR0000046317" dictionary="Cancer.gov" audience="Patient">laryngeal</GlossaryTermRef>, lung, or <GlossaryTermRef href="CDR0000046408" dictionary="Cancer.gov" audience="Patient">esophageal</GlossaryTermRef>) when adjusting for several confounders, including cigarette smoking.<Reference refidx="11"/></Para><Para id="_116">A systematic review of 19 studies evaluating <GlossaryTermRef href="CDR0000045846" dictionary="Cancer.gov" audience="Patient">premalignant</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045772" dictionary="Cancer.gov" audience="Patient">malignant</GlossaryTermRef> lung <GlossaryTermRef href="CDR0000046324" dictionary="Cancer.gov" audience="Patient">lesions</GlossaryTermRef> in people 18 years or older who inhaled <ScientificName>Cannabis</ScientificName>   concluded that <GlossaryTermRef href="CDR0000286105" dictionary="Cancer.gov" audience="Patient">observational studies</GlossaryTermRef> failed to demonstrate a <GlossaryTermRef href="CDR0000044167" dictionary="Cancer.gov" audience="Patient">statistically significant</GlossaryTermRef> association between <ScientificName>Cannabis</ScientificName> inhalation and lung cancer after adjusting for tobacco use.<Reference refidx="12"/> In the review of the published <GlossaryTermRef href="CDR0000691484" dictionary="Cancer.gov" audience="Patient">meta-analyses</GlossaryTermRef>, the National Academies of Sciences, Engineering, and Medicine (NASEM) report concluded that there was moderate evidence of no statistical association between <ScientificName>Cannabis</ScientificName> smoking and the <GlossaryTermRef href="CDR0000046145" dictionary="Cancer.gov" audience="Patient">incidence</GlossaryTermRef> of lung cancer.<Reference refidx="13"/></Para><Para id="_201"><GlossaryTermRef href="CDR0000257225" dictionary="Cancer.gov" audience="Patient">Epidemiological</GlossaryTermRef> studies examining one association of <ScientificName>Cannabis</ScientificName> use with <GlossaryTermRef href="CDR0000597171" dictionary="Cancer.gov" audience="Patient">head and neck squamous cell carcinomas</GlossaryTermRef> have also been inconsistent in their findings. A pooled analysis of nine case-control studies from the U.S./Latin  American International Head and Neck Cancer Epidemiology (INHANCE) Consortium included information from 1,921 <GlossaryTermRef href="CDR0000046024" dictionary="Cancer.gov" audience="Patient">oropharyngeal</GlossaryTermRef> cancer cases, 356 tongue cancer cases, and 7,639 controls. The study found that   <ScientificName>Cannabis</ScientificName> smokers had an elevated risk of <GlossaryTermRef href="CDR0000446523" dictionary="Cancer.gov" audience="Patient">oropharyngeal cancers</GlossaryTermRef> and a reduced risk of <GlossaryTermRef href="CDR0000390285" dictionary="Cancer.gov" audience="Patient">tongue cancer</GlossaryTermRef> compared with those who never smoked <ScientificName>Cannabis</ScientificName>.  These study results both reflect  the inconsistent  effects of cannabinoids  on cancer incidence noted in previous studies and suggest that more research is needed to understand the potential role of <GlossaryTermRef href="CDR0000045714" dictionary="Cancer.gov" audience="Patient">human papillomavirus</GlossaryTermRef> <GlossaryTermRef href="CDR0000045364" dictionary="Cancer.gov" audience="Patient">infection</GlossaryTermRef>.<Reference refidx="14"/> A systematic review and <GlossaryTermRef href="CDR0000691484" dictionary="Cancer.gov" audience="Patient">meta-analysis</GlossaryTermRef> of nine case-control studies involving 13,931 participants also concluded that there was insufficient evidence to demonstrate a positive or negative association between <ScientificName>Cannabis</ScientificName> smoking and the incidence of <GlossaryTermRef href="CDR0000257519" dictionary="Cancer.gov" audience="Patient">head and neck cancers</GlossaryTermRef>.<Reference refidx="15"/></Para><Para id="_177">Stimulated by the <GlossaryTermRef href="CDR0000044209" dictionary="Cancer.gov" audience="Patient">hypothesis</GlossaryTermRef> that chronic <GlossaryTermRef href="CDR0000285927" dictionary="Cancer.gov" audience="Patient">marijuana</GlossaryTermRef> use produces <GlossaryTermRef href="CDR0000044922" dictionary="Cancer.gov" audience="Patient">adverse effects</GlossaryTermRef> on the human <GlossaryTermRef href="CDR0000468796" dictionary="Cancer.gov" audience="Patient">endocrine</GlossaryTermRef> and <GlossaryTermRef href="CDR0000046564" dictionary="Cancer.gov" audience="Patient">reproductive systems</GlossaryTermRef>,  the association between <ScientificName>Cannabis</ScientificName> use and incidence of <GlossaryTermRef href="CDR0000695185" dictionary="Cancer.gov" audience="Patient">testicular germ cell tumors</GlossaryTermRef> (TGCTs) has been examined.<Reference refidx="16"/><Reference refidx="17"/><Reference refidx="18"/> Three population-based case-control studies reported an association between <ScientificName>Cannabis</ScientificName> use and elevated risk of TGCTs, especially <GlossaryTermRef href="CDR0000046255" dictionary="Cancer.gov" audience="Patient">nonseminoma</GlossaryTermRef> or mixed-<GlossaryTermRef href="CDR0000044171" dictionary="Cancer.gov" audience="Patient">histology</GlossaryTermRef> tumors.<Reference refidx="16"/><Reference refidx="17"/><Reference refidx="18"/> However, the sample sizes in these studies were inadequate to address <ScientificName>Cannabis</ScientificName> <GlossaryTermRef href="CDR0000044664" dictionary="Cancer.gov" audience="Patient">dose</GlossaryTermRef> by  addressing associations among recency, frequency, and duration of use. In a study of 49,343  Swedish men aged 19 to 21 years enrolled in the military between 1969 and 1970, participants were asked at the time of conscription about their use of <ScientificName>Cannabis</ScientificName> and were followed up for 42 years.<Reference refidx="19"/> This study found no significant correlation between “ever” <ScientificName>Cannabis</ScientificName> use and the development of <GlossaryTermRef href="CDR0000445090" dictionary="Cancer.gov" audience="Patient">testicular cancer</GlossaryTermRef>, but it did find that “heavy” <ScientificName>Cannabis</ScientificName> use (more than 50 times in a lifetime) was associated with a 2.5-fold increased risk. Limitations of the study were that it relied on indirect <GlossaryTermRef href="CDR0000430407" dictionary="Cancer.gov" audience="Patient">assessment</GlossaryTermRef> of <ScientificName>Cannabis</ScientificName> use, and no information was collected on <ScientificName>Cannabis</ScientificName> use after the conscription-assessment period or on whether the testicular cancers were <GlossaryTermRef href="CDR0000046577" dictionary="Cancer.gov" audience="Patient">seminoma</GlossaryTermRef> or nonseminoma subtypes. These  reports established the need for larger, well-powered, <GlossaryTermRef href="CDR0000044079" dictionary="Cancer.gov" audience="Patient">prospective studies</GlossaryTermRef>,  especially studies evaluating the role of endocannabinoid signaling and cannabinoid <GlossaryTermRef href="CDR0000044958" dictionary="Cancer.gov" audience="Patient">receptors</GlossaryTermRef> in TGCTs.</Para><Para id="_226">An analysis of 84,170 participants in the California Men’s Health Study was performed to investigate the association between <Emphasis>Cannabis</Emphasis> use and the incidence of <GlossaryTermRef href="CDR0000444968" dictionary="Cancer.gov" audience="Patient">bladder cancer</GlossaryTermRef>. During 16 years of <GlossaryTermRef href="CDR0000044671" dictionary="Cancer.gov" audience="Patient">follow-up</GlossaryTermRef>, 89 <Emphasis>Cannabis</Emphasis> users (0.3%) developed bladder cancer compared with 190 (0.4%) of the men who did not report <Emphasis>Cannabis</Emphasis> use (<Emphasis>P</Emphasis> &lt; .001). After adjusting for age, <GlossaryTermRef href="CDR0000784947" dictionary="Cancer.gov" audience="Patient">race</GlossaryTermRef>, ethnicity, and <GlossaryTermRef href="CDR0000455136" dictionary="Cancer.gov" audience="Patient">body mass index</GlossaryTermRef>, <Emphasis>Cannabis</Emphasis> use was associated with a 45% reduction in bladder cancer incidence (<GlossaryTermRef href="CDR0000618612" dictionary="Cancer.gov" audience="Patient">hazard ratio</GlossaryTermRef>, 0.55; 95%  confidence interval [CI], 0.33–1.00).<Reference refidx="20"/></Para><Para id="_115">A comprehensive Health Canada monograph on marijuana concluded that while there are many cellular and molecular studies that provide strong evidence that inhaled marijuana is carcinogenic, the epidemiological evidence of a link between marijuana use and cancer is still <GlossaryTermRef href="CDR0000556498" dictionary="Genetics" audience="Health professional">inconclusive</GlossaryTermRef>.<Reference refidx="21"/></Para></SummarySection><SummarySection id="_287"><Title>Patterns of <ScientificName>Cannabis</ScientificName> Use Among Cancer Patients</Title><Para id="_288">A cross-sectional survey of patients with cancer seen at the Seattle Cancer Care Alliance was conducted over a 6-week period between 2015 and 2016.<Reference refidx="22"/> In Washington State, <ScientificName>Cannabis</ScientificName> was legalized for medicinal use in 1998 and for recreational use in 2012. Of the 2,737 possible participants, 936 (34%) completed the anonymous questionnaire. Twenty-four percent of patients considered themselves active <ScientificName>Cannabis</ScientificName> users. Similar numbers of patients inhaled (70%) or used edibles (70%), with dual use (40%) being common. Non–mutually exclusive reasons for <ScientificName>Cannabis</ScientificName> use were physical <GlossaryTermRef href="CDR0000045022" dictionary="Cancer.gov" audience="Patient">symptoms</GlossaryTermRef> (75%), neuropsychiatric symptoms (63%), recreational use/enjoyment (35%), and treatment of cancer (26%). The physical symptoms most commonly cited were pain, <GlossaryTermRef href="CDR0000390302" dictionary="Cancer.gov" audience="Patient">nausea,</GlossaryTermRef> and loss of  <GlossaryTermRef href="CDR0000454699" dictionary="Cancer.gov" audience="Patient">appetite</GlossaryTermRef>. Most patients (74%) stated that they would prefer to obtain information about <ScientificName>Cannabis</ScientificName> from their cancer team, but less than 15% reported receiving information from their cancer <GlossaryTermRef href="CDR0000390246" dictionary="Cancer.gov" audience="Patient">physician</GlossaryTermRef> or <GlossaryTermRef href="CDR0000269445" dictionary="Cancer.gov" audience="Patient">nurse</GlossaryTermRef>.</Para><Para id="_335">Data from 2,970 Israeli patients with cancer who used  government-issued <ScientificName>Cannabis</ScientificName> were collected over a 6-month period to assess for improvement in <GlossaryTermRef href="CDR0000467830" dictionary="Cancer.gov" audience="Patient">baseline</GlossaryTermRef> symptoms.<Reference refidx="23"/> The most improved symptoms from baseline include the following:</Para><ItemizedList id="_336" Style="bullet">
     <ListItem>Nausea and <GlossaryTermRef href="CDR0000390324" dictionary="Cancer.gov" audience="Patient">vomiting</GlossaryTermRef> (91.0%).</ListItem><ListItem><GlossaryTermRef href="CDR0000454814" dictionary="Cancer.gov" audience="Patient">Sleep disorders</GlossaryTermRef> (87.5%).</ListItem><ListItem>Restlessness (87.5%).</ListItem><ListItem><GlossaryTermRef href="CDR0000430405" dictionary="Cancer.gov" audience="Patient">Anxiety</GlossaryTermRef> and <GlossaryTermRef href="CDR0000430479" dictionary="Cancer.gov" audience="Patient">depression</GlossaryTermRef> (84.2%).</ListItem><ListItem><GlossaryTermRef href="CDR0000446534" dictionary="Cancer.gov" audience="Patient">Pruritus</GlossaryTermRef> (82.1%).</ListItem><ListItem>Headaches (81.4%).</ListItem></ItemizedList><Para id="_337">Before  treatment initiation,  52.9% of patients reported pain scores in the 8 to 10 range, while only 4.6% of patients  reported this intensity at the 6-month assessment time point. It is difficult to assess from the observational data if the improvements were caused by  the <ScientificName>Cannabis</ScientificName> or the cancer  treatment.<Reference refidx="23"/> Similarly, a study of a subset of patients with cancer  in the Minnesota medical <ScientificName>Cannabis</ScientificName> program explored changes in the severity of eight symptoms (i.e., anxiety, appetite loss, depression, disturbed sleep, fatigue, nausea, pain, and vomiting) experienced by these patients.<Reference refidx="24"/> Significant symptomatic improvements were noted (38.4%–56.2%) in patients with each symptom. Because of  the observational and uncontrolled nature of this study, the findings are not generalizable, but as the authors suggested, may be useful in designing more rigorous <GlossaryTermRef href="CDR0000651211" dictionary="Cancer.gov" audience="Patient">research studies</GlossaryTermRef> in the future.</Para><Para id="_370">Forty-two percent of women (257 of 612) with a <GlossaryTermRef href="CDR0000046450" dictionary="Cancer.gov" audience="Patient">diagnosis</GlossaryTermRef> of <GlossaryTermRef href="CDR0000444971" dictionary="Cancer.gov" audience="Patient">breast cancer</GlossaryTermRef> within the past 5 years who participated in an anonymous online survey reported using <ScientificName>Cannabis</ScientificName> for the relief of symptoms, particularly pain (78%), <GlossaryTermRef href="CDR0000044043" dictionary="Cancer.gov" audience="Patient">insomnia</GlossaryTermRef> (70%), anxiety (57%), <GlossaryTermRef href="CDR0000450122" dictionary="Cancer.gov" audience="Patient">stress</GlossaryTermRef> (51%), and nausea and vomiting (46%).<Reference refidx="25"/> Among <ScientificName>Cannabis</ScientificName> users,  79% used <ScientificName>Cannabis</ScientificName> during their cancer treatment, and 75% reported that <ScientificName>Cannabis</ScientificName> was extremely or very helpful for relieving symptoms. Forty-nine percent of <ScientificName>Cannabis</ScientificName> users felt that <ScientificName>Cannabis</ScientificName>  could be useful in treating the cancer itself. Only 39% of the participants reported discussing  <ScientificName>Cannabis</ScientificName> use with their physicians.</Para><Para id="_392">Patients with cancer turn to medical <ScientificName>Cannabis</ScientificName> use even in states where it has not been legalized. Researchers from the Medical University of South Carolina conducted a survey study that explored the <GlossaryTermRef href="CDR0000789737" dictionary="Cancer.gov" audience="Patient">prevalence</GlossaryTermRef>, patterns, and motivations behind <ScientificName>Cannabis</ScientificName> use among patients with cancer and <GlossaryTermRef href="CDR0000450125" dictionary="Cancer.gov" audience="Patient">survivors</GlossaryTermRef> in a state without legal access to <ScientificName>Cannabis</ScientificName> as of 2023.<Reference refidx="26"/> Despite the absence of legal access, a significant proportion of participants reported using <ScientificName>Cannabis</ScientificName> for  <GlossaryTermRef href="CDR0000269453" dictionary="Cancer.gov" audience="Patient">symptom management</GlossaryTermRef> including pain, nausea, and other symptoms. Moreover, participants reported improvements in mood, sleep, and overall better <GlossaryTermRef href="CDR0000045417" dictionary="Cancer.gov" audience="Patient">quality of life</GlossaryTermRef>.   This study gives insight into why many patients with cancer and survivors use <ScientificName>Cannabis</ScientificName> for symptom management, highlighting the importance of understanding and addressing patient' needs even in states with no legal access to <ScientificName>Cannabis</ScientificName>.</Para></SummarySection><SummarySection id="_73"><Title>Cancer Treatment</Title><Para id="_74"> No ongoing clinical trials of <ScientificName>Cannabis</ScientificName> as a treatment for cancer in humans were identified in a PubMed search. The first published trial of any cannabinoid in patients with cancer was a small pilot study of <GlossaryTermRef href="CDR0000044603" dictionary="Cancer.gov" audience="Patient">intratumoral</GlossaryTermRef> <GlossaryTermRef href="CDR0000044678" dictionary="Cancer.gov" audience="Patient">injection</GlossaryTermRef> of delta-9-THC  in patients with <GlossaryTermRef href="CDR0000045862" dictionary="Cancer.gov" audience="Patient">recurrent</GlossaryTermRef> <GlossaryTermRef href="CDR0000045699" dictionary="Cancer.gov" audience="Patient">glioblastoma multiforme</GlossaryTermRef>, which demonstrated no significant clinical benefit.<Reference refidx="27"/><Reference refidx="28"/> A small <GlossaryTermRef href="CDR0000045673" dictionary="Cancer.gov" audience="Patient">double-blind</GlossaryTermRef> exploratory phase IB study, conducted in the United Kingdom, used nabiximols, a 1:1 ratio of THC:CBD in a <ScientificName>Cannabis</ScientificName>-based medicinal extract oromucosal spray, in conjunction with dose-dense <GlossaryTermRef href="CDR0000045387" dictionary="Cancer.gov" audience="Patient">temozolomide</GlossaryTermRef> in treating patients with recurrent glioblastoma multiforme.<Reference refidx="29"/>[<LOERef href="CDR0000335106" dictionary="NotSet" audience="Health professional">Level of evidence: 1iA</LOERef>] Of the 27  patients enrolled, 6 were part of an open-label group and 21 were part of a <GlossaryTermRef href="CDR0000045858" dictionary="Cancer.gov" audience="Patient">randomized</GlossaryTermRef> group (12 treated with nabiximols and 9 treated with <GlossaryTermRef href="CDR0000046688" dictionary="Cancer.gov" audience="Patient">placebo</GlossaryTermRef>). <GlossaryTermRef href="CDR0000044782" dictionary="Cancer.gov" audience="Patient">Progression-free survival</GlossaryTermRef> at 6 months was seen in 33% of patients in both arms of the study. However, at 1 year, 83.3% of the patients who received nabiximols were alive compared with 44.4% of those who received placebo  (<Emphasis>P</Emphasis> = .042). The investigators cautioned that this early-phase study was not powered for a survival <GlossaryTermRef href="CDR0000346519" dictionary="Cancer.gov" audience="Patient">end point</GlossaryTermRef>. <GlossaryTermRef href="CDR0000655245" dictionary="Cancer.gov" audience="Patient">Overall survival</GlossaryTermRef> rates at 2 years continued to favor the nabiximols arm (50%) compared with the placebo arm (22%) (these rates included results for the 6 patients in the open-label group who received nabiximols).<Reference refidx="29"/></Para><Para id="_325">In a  2016 <GlossaryTermRef href="CDR0000285747" dictionary="Cancer.gov" audience="Patient">consecutive case series</GlossaryTermRef> study,  nine patients with varying <GlossaryTermRef href="CDR0000045885" dictionary="Cancer.gov" audience="Patient">stages</GlossaryTermRef> of <GlossaryTermRef href="CDR0000387264" dictionary="Cancer.gov" audience="Patient">brain tumors</GlossaryTermRef>, including six with glioblastoma multiforme, received CBD 200 mg twice daily in addition to <GlossaryTermRef href="CDR0000045570" dictionary="Cancer.gov" audience="Patient">surgical</GlossaryTermRef> <GlossaryTermRef href="CDR0000269459" dictionary="Cancer.gov" audience="Patient">excision</GlossaryTermRef> and <GlossaryTermRef href="CDR0000306495" dictionary="Cancer.gov" audience="Patient">chemoradiation</GlossaryTermRef>.<Reference refidx="30"/>[<LOERef href="CDR0000335150" dictionary="NotSet" audience="Health professional">Level of evidence: 3iiiA</LOERef>] The authors reported that all but one of the <GlossaryTermRef href="CDR0000561393" dictionary="Cancer.gov" audience="Patient">cohort</GlossaryTermRef> remained alive at the time of publication. However, the <GlossaryTermRef href="CDR0000044807" dictionary="Cancer.gov" audience="Patient">heterogeneity</GlossaryTermRef> of the brain tumor patients probably contributed to the findings.</Para><Para id="_270">Another Israeli group postulated that the <GlossaryTermRef href="CDR0000044187" dictionary="Cancer.gov" audience="Patient">anti-inflammatory</GlossaryTermRef> and <GlossaryTermRef href="CDR0000044041" dictionary="Cancer.gov" audience="Patient">immunosuppressive</GlossaryTermRef> effects of CBD might make it a valuable <GlossaryTermRef href="CDR0000367454" dictionary="Cancer.gov" audience="Patient">adjunct</GlossaryTermRef> in the treatment of <GlossaryTermRef href="CDR0000045585" dictionary="Cancer.gov" audience="Patient">acute</GlossaryTermRef> <GlossaryTermRef href="CDR0000045703" dictionary="Cancer.gov" audience="Patient">graft-versus-host disease</GlossaryTermRef> (GVHD) in patients who have undergone <GlossaryTermRef href="CDR0000270732" dictionary="Cancer.gov" audience="Patient">allogeneic hematopoietic stem cell transplant</GlossaryTermRef>. The authors investigated CBD 300 mg/d in addition to standard GVHD <GlossaryTermRef href="CDR0000046538" dictionary="Cancer.gov" audience="Patient">prophylaxis</GlossaryTermRef> in 48 adult patients who had undergone a transplant, predominantly for <GlossaryTermRef href="CDR0000045145" dictionary="Cancer.gov" audience="Patient">acute leukemia</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045266" dictionary="Cancer.gov" audience="Patient">myelodysplastic syndrome</GlossaryTermRef> (<ProtocolRef nct_id="NCT01385124">NCT01385124</ProtocolRef> and <ProtocolRef nct_id="NCT01596075">NCT01596075</ProtocolRef>).<Reference refidx="31"/> The combination of CBD with standard GVHD prophylaxis was found to be safe. Compared with 101 <GlossaryTermRef href="CDR0000044596" dictionary="Cancer.gov" audience="Patient">historical controls</GlossaryTermRef> treated with standard prophylaxis, patients who received CBD appeared to have a lower incidence of grade II to grade IV GVHD, suggesting that a randomized <GlossaryTermRef href="CDR0000044014" dictionary="Cancer.gov" audience="Patient">controlled trial</GlossaryTermRef> (RCT) is warranted.</Para><Para id="_271">Clinical data regarding <ScientificName>Cannabis</ScientificName> as an <GlossaryTermRef href="CDR0000639945" dictionary="Cancer.gov" audience="Patient">anticancer agent</GlossaryTermRef> in <GlossaryTermRef href="CDR0000046245" dictionary="Cancer.gov" audience="Patient">pediatric</GlossaryTermRef> use are limited to a few <GlossaryTermRef href="CDR0000044007" dictionary="Cancer.gov" audience="Patient">case reports</GlossaryTermRef>.<Reference refidx="32"/><Reference refidx="33"/></Para><Para id="_400">A review of medical literature shows evidence of a growing interest in research of the use of <ScientificName>Cannabis</ScientificName> in cancer management.<Reference refidx="34"/></Para></SummarySection><SummarySection id="_40"><Title>Antiemetic Effect</Title><SummarySection id="_81"><Title>Cannabinoids</Title><Para id="_41">Despite advances in <GlossaryTermRef href="CDR0000463167" dictionary="Cancer.gov" audience="Patient">pharmacological</GlossaryTermRef> and nonpharmacological management, nausea and vomiting (N/V) remain distressing <GlossaryTermRef href="CDR0000046580" dictionary="Cancer.gov" audience="Patient">side effects</GlossaryTermRef> for patients with cancer and their families.  <GlossaryTermRef href="CDR0000045240" dictionary="Cancer.gov" audience="Patient">Dronabinol</GlossaryTermRef>, a <GlossaryTermRef href="CDR0000462950" dictionary="Cancer.gov" audience="Patient">synthetically</GlossaryTermRef> produced delta-9-THC,  was approved in the United States in 1986 as an <GlossaryTermRef href="CDR0000046084" dictionary="Cancer.gov" audience="Patient">antiemetic</GlossaryTermRef> to be used in cancer <GlossaryTermRef href="CDR0000045214" dictionary="Cancer.gov" audience="Patient">chemotherapy</GlossaryTermRef>.  <GlossaryTermRef href="CDR0000716290" dictionary="Cancer.gov" audience="Patient">Nabilone</GlossaryTermRef>, a synthetic derivative of delta-9-THC, was first approved in Canada in 1982 and is now also available in the United States.<Reference refidx="35"/>  The <GlossaryTermRef href="CDR0000454785" dictionary="Cancer.gov" audience="Patient">U.S. Food and Drug Administration</GlossaryTermRef> (FDA) has approved both dronabinol and nabilone for the treatment of N/V associated with cancer chemotherapy in patients who have failed to <GlossaryTermRef href="CDR0000044085" dictionary="Cancer.gov" audience="Patient">respond</GlossaryTermRef> to conventional antiemetic <GlossaryTermRef href="CDR0000044737" dictionary="Cancer.gov" audience="Patient">therapy</GlossaryTermRef>.  Numerous <GlossaryTermRef href="CDR0000044168" dictionary="Cancer.gov" audience="Patient">clinical</GlossaryTermRef> trials and <GlossaryTermRef href="CDR0000691484" dictionary="Cancer.gov" audience="Patient">meta-analyses</GlossaryTermRef> have shown that dronabinol and nabilone are effective in the treatment of N/V induced by chemotherapy.<Reference refidx="36"/><Reference refidx="37"/><Reference refidx="38"/><Reference refidx="39"/> The National Comprehensive Cancer Network Guidelines recommend cannabinoids as breakthrough treatment for chemotherapy-related N/V.<Reference refidx="40"/> The American Society for Clinical Oncology (ASCO) antiemetic guidelines updated in 2017 recommends that the FDA-approved cannabinoids,  dronabinol or nabilone, be used  to treat N/V that is resistant to standard antiemetic therapies.<Reference refidx="41"/></Para><Para id="_42">One systematic review studied 30 randomized comparisons of delta-9-THC preparations  with placebo or other antiemetics from which data on <GlossaryTermRef href="CDR0000346517" dictionary="Cancer.gov" audience="Patient">efficacy</GlossaryTermRef> and harm were available.<Reference refidx="42"/> Oral nabilone, oral dronabinol, and <GlossaryTermRef href="CDR0000044048" dictionary="Cancer.gov" audience="Patient">intramuscular</GlossaryTermRef> levonantradol (a synthetic <GlossaryTermRef href="CDR0000044919" dictionary="Cancer.gov" audience="Patient">analogue</GlossaryTermRef> of dronabinol) were tested.  Inhaled <ScientificName>Cannabis</ScientificName> trials were not included.  Among all 1,366 patients included in the review, cannabinoids were found to be more effective than the conventional antiemetics <GlossaryTermRef href="CDR0000045232" dictionary="Cancer.gov" audience="Patient">prochlorperazine</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045225" dictionary="Cancer.gov" audience="Patient">metoclopramide</GlossaryTermRef>, chlorpromazine, <GlossaryTermRef href="CDR0000467870" dictionary="Cancer.gov" audience="Patient">thiethylperazine</GlossaryTermRef>, <GlossaryTermRef href="CDR0000476306" dictionary="Cancer.gov" audience="Patient">haloperidol</GlossaryTermRef>, domperidone, and alizapride. Cannabinoids, however, were not more effective for patients receiving very low or very high <GlossaryTermRef href="CDR0000454776" dictionary="Cancer.gov" audience="Patient">emetogenic</GlossaryTermRef> chemotherapy.  Side effects included a feeling of being high, <GlossaryTermRef href="CDR0000468801" dictionary="Cancer.gov" audience="Patient">euphoria</GlossaryTermRef>, <GlossaryTermRef href="CDR0000450118" dictionary="Cancer.gov" audience="Patient">sedation</GlossaryTermRef> or drowsiness,  dizziness, dysphoria or depression, <GlossaryTermRef href="CDR0000476341" dictionary="Cancer.gov" audience="Patient">hallucinations</GlossaryTermRef>, <GlossaryTermRef href="CDR0000468802" dictionary="Cancer.gov" audience="Patient">paranoia</GlossaryTermRef>, and <GlossaryTermRef href="CDR0000044039" dictionary="Cancer.gov" audience="Patient">hypotension</GlossaryTermRef>.<Reference refidx="42"/> </Para><Para id="_43">Another analysis of 15 <GlossaryTermRef href="CDR0000044015" dictionary="Cancer.gov" audience="Patient">controlled studies</GlossaryTermRef> compared nabilone with placebo or available antiemetic drugs.<Reference refidx="43"/> Among 600 patients with cancer, nabilone was found to be superior to prochlorperazine, domperidone, and alizapride, with nabilone favored for continuous use.</Para><Para id="_261">A Cochrane meta-analysis of 23 RCTs reviewed studies conducted between 1975 and 1991 that investigated dronabinol or nabilone, either as <GlossaryTermRef href="CDR0000754011" dictionary="Cancer.gov" audience="Patient">monotherapy</GlossaryTermRef> or as an adjunct to the <GlossaryTermRef href="CDR0000044198" dictionary="Cancer.gov" audience="Patient">conventional</GlossaryTermRef> dopamine <GlossaryTermRef href="CDR0000350250" dictionary="Cancer.gov" audience="Patient">antagonists</GlossaryTermRef> that were  the <GlossaryTermRef href="CDR0000044930" dictionary="Cancer.gov" audience="Patient">standard</GlossaryTermRef> antiemetics at that time.<Reference refidx="44"/> The chemotherapy <GlossaryTermRef href="CDR0000045864" dictionary="Cancer.gov" audience="Patient">regimens</GlossaryTermRef> involved drugs with low, moderate, or high <GlossaryTermRef href="CDR0000467221" dictionary="Cancer.gov" audience="Patient">emetic</GlossaryTermRef> potential. The meta-analysis graded the quality of evidence as low for most outcomes. The review concluded that individuals were more likely to report complete absence of N/V when they received cannabinoids compared with placebo, although they were more likely to withdraw from the study because of an adverse event. Individuals reported a higher preference for cannabinoids than placebo or prochlorperazine. There was no difference in the antiemetic effect of cannabinoids when compared with prochlorperazine. The authors concluded that <ScientificName>Cannabis</ScientificName>-based medications may be useful for treating <GlossaryTermRef href="CDR0000350245" dictionary="Cancer.gov" audience="Patient">refractory</GlossaryTermRef> chemotherapy-induced N/V; however, they cautioned that their assessment may change with the availability of newer antiemetic regimens.</Para><Para id="_269">At least 50% of patients who receive moderately emetogenic chemotherapy may experience delayed chemotherapy-induced N/V. Although selective neurokinin 1 antagonists that inhibit substance P have been approved for delayed N/V, a study was conducted before their availability to assess dronabinol, <GlossaryTermRef href="CDR0000616146" dictionary="Cancer.gov" audience="Patient">ondansetron</GlossaryTermRef>, or their combination in preventing delayed-onset chemotherapy-induced N/V.<Reference refidx="45"/> Ondansetron, a serotonin 5-hydroxytryptamine 3 <GlossaryTermRef href="CDR0000467824" dictionary="Cancer.gov" audience="Patient">(5-HT3) receptor antagonist</GlossaryTermRef>, is one of the mainstay agents in the current antiemetic armamentarium. In this  trial, the primary objective was to assess the response 2 to 5 days after moderately to severely emetogenic chemotherapy. Sixty-one patients were analyzed for efficacy. The total response—a composite end point—including nausea intensity, vomiting/retching, and use of rescue medications, was similar with dronabinol (54%), ondansetron (58%), and combination therapy (47%) when compared with placebo (20%). Nausea absence was greater in the active treatment groups (dronabinol 71%, ondansetron 64%, combination therapy 53%) when compared with placebo (15%; <Emphasis>P</Emphasis> &lt; .05 vs. placebo for all). Occurrence rates for nausea intensity and vomiting/retching episodes were the lowest in patients treated with dronabinol, suggesting that dronabinol compares favorably with ondansetron in this situation where a substance P inhibitor would currently be the drug of choice.</Para><Para id="_107">For more information, see  the <ScientificName><SummaryRef href="CDR0000062747#_457" url="/about-cancer/treatment/side-effects/nausea/nausea-hp-pdq">Cannabis</SummaryRef></ScientificName> section in Nausea and Vomiting Related to Cancer Treatment.</Para></SummarySection><SummarySection id="_82"><Title><ScientificName>Cannabis</ScientificName></Title><Para id="_44">Three trials have evaluated the efficacy of inhaled <ScientificName>Cannabis</ScientificName> in chemotherapy-induced N/V.<Reference refidx="46"/><Reference refidx="47"/><Reference refidx="48"/><Reference refidx="49"/>
  In two of the studies,  inhaled <ScientificName>Cannabis</ScientificName> was  made available only after dronabinol failure.  In the first trial, no antiemetic effect was achieved with marijuana in patients receiving <GlossaryTermRef href="CDR0000045253" dictionary="Cancer.gov" audience="Patient">cyclophosphamide</GlossaryTermRef> or <GlossaryTermRef href="CDR0000560140" dictionary="Cancer.gov" audience="Patient">doxorubicin</GlossaryTermRef>,<Reference refidx="46"/> but in the second trial, a <GlossaryTermRef href="CDR0000044167" dictionary="Cancer.gov" audience="Patient">statistically significant</GlossaryTermRef> superior  antiemetic effect  of inhaled <ScientificName>Cannabis</ScientificName> versus placebo was found among patients receiving high-dose <GlossaryTermRef href="CDR0000045393" dictionary="Cancer.gov" audience="Patient">methotrexate</GlossaryTermRef>.<Reference refidx="47"/> The third trial was a randomized, double-blind, <GlossaryTermRef href="CDR0000044840" dictionary="Cancer.gov" audience="Patient">placebo-controlled</GlossaryTermRef>, crossover trial involving 20 adults in which both inhaled marijuana and oral THC were evaluated.  One-quarter of the patients reported a favorable antiemetic response to the cannabinoid <GlossaryTermRef href="CDR0000044737" dictionary="Cancer.gov" audience="Patient">therapies</GlossaryTermRef>. This latter study was reported in abstract form in 1984.  A full report, detailing the methods and outcomes apparently has not been published,  which limits a thorough interpretation of the significance of these findings.<Reference refidx="48"/></Para><Para id="_255">Newer antiemetics (e.g., 5-HT3 receptor antagonists) have not been directly compared with <ScientificName>Cannabis</ScientificName> or cannabinoids in patients with cancer.  However, the <ScientificName>Cannabis</ScientificName>-extract oromucosal spray, nabiximols, formulated with 1:1 THC:CBD was shown in a small <GlossaryTermRef href="CDR0000045838" dictionary="Cancer.gov" audience="Patient">pilot</GlossaryTermRef> randomized, placebo-controlled, double-blinded clinical trial in Spain to treat chemotherapy-related N/V.<Reference refidx="50"/>[<LOERef href="CDR0000335121" dictionary="NotSet" audience="Health professional">Level of evidence: 1iC</LOERef>] </Para><Para id="_402">A <GlossaryTermRef href="CDR0000045834" dictionary="Cancer.gov" audience="Patient">phase II/III</GlossaryTermRef> Australian/New Zealand trial included patients with a <GlossaryTermRef href="CDR0000045301" dictionary="Cancer.gov" audience="Patient">solid tumor</GlossaryTermRef> or hematological malignancy of any stage (n = 147). Patients received a THC:CBD <GlossaryTermRef href="CDR0000455334" dictionary="Cancer.gov" audience="Patient">capsule</GlossaryTermRef> or placebo on days -1 to 5 for the secondary <GlossaryTermRef href="CDR0000439419" dictionary="Cancer.gov" audience="Patient">prevention</GlossaryTermRef> of refractory chemotherapy-induced N/V in combination with guideline recommended antiemetics for chemotherapy of moderate or high emetogenic risk.<Reference refidx="51"/> The <GlossaryTermRef href="CDR0000044163" dictionary="Cancer.gov" audience="Patient">primary end point</GlossaryTermRef> was <GlossaryTermRef href="CDR0000045652" dictionary="Cancer.gov" audience="Patient">complete response</GlossaryTermRef>, defined as no <GlossaryTermRef href="CDR0000256560" dictionary="Cancer.gov" audience="Patient">emesis</GlossaryTermRef> or use of rescue medications during hours 0–120. The THC:CBD group had a higher <GlossaryTermRef href="CDR0000043983" dictionary="Cancer.gov" audience="Patient">response rate</GlossaryTermRef> (24%) compared with the placebo group (8%). Increased moderate- to-severe side effects were observed in the <GlossaryTermRef href="CDR0000044681" dictionary="Cancer.gov" audience="Patient">intervention group</GlossaryTermRef> with more frequent sedation, transient anxiety, and dizziness.</Para><Para id="_319">ASCO antiemetic guidelines updated in 2020 state that evidence remains insufficient to recommend medical marijuana for either the prevention or treatment of N/V in patients with cancer who receive chemotherapy or <GlossaryTermRef href="CDR0000044971" dictionary="Cancer.gov" audience="Patient">radiation therapy</GlossaryTermRef>.<Reference refidx="41"/></Para></SummarySection></SummarySection><SummarySection id="_45"><Title>Appetite Stimulation</Title><Para id="_46">Patients with cancer may experience <GlossaryTermRef href="CDR0000044103" dictionary="Cancer.gov" audience="Patient">anorexia</GlossaryTermRef>, early satiety, weight loss, and <GlossaryTermRef href="CDR0000044108" dictionary="Cancer.gov" audience="Patient">cachexia</GlossaryTermRef>.  Such patients  face not only the disfigurement associated with wasting but also cannot engage in the social interaction of meals.</Para><SummarySection id="_83"><Title>Cannabinoids</Title><Para id="_48">Four controlled trials have assessed the effect of oral THC on measures of appetite, food appreciation, <GlossaryTermRef href="CDR0000044651" dictionary="Cancer.gov" audience="Patient">calorie</GlossaryTermRef> intake,  and  weight loss in patients with advanced malignancies. Three relatively small, placebo-controlled trials (N = 52; N = 46; N = 65) each found that oral THC produced improvements in one or more of these outcomes.<Reference refidx="52"/><Reference refidx="53"/><Reference refidx="54"/> The one study that used an active control evaluated the efficacy of dronabinol alone or with <GlossaryTermRef href="CDR0000046617" dictionary="Cancer.gov" audience="Patient">megestrol</GlossaryTermRef> <GlossaryTermRef href="CDR0000655020" dictionary="Cancer.gov" audience="Patient">acetate</GlossaryTermRef> compared with that of megestrol acetate alone for managing cancer-associated anorexia.<Reference refidx="55"/>   In this randomized, double-blind study of 469 adults with <GlossaryTermRef href="CDR0000478743" dictionary="Cancer.gov" audience="Patient">advanced cancer</GlossaryTermRef> and weight loss, patients received  2.5 mg of oral THC twice daily, 800 mg of oral megestrol daily, or both. After 8 to 11 weeks of treatment, the megestrol group had a 75% increase in appetite and an 11% increase in weight, compared with a 49% increase in appetite and a 3% increase in weight in the oral THC group. The between-group differences were statistically <GlossaryTermRef href="CDR0000390271" dictionary="Cancer.gov" audience="Patient">significant</GlossaryTermRef> in favor of megestrol acetate.  Furthermore, the combined therapy did not offer additional benefits beyond those provided by megestrol acetate alone. The authors concluded that dronabinol, compared with megestrol acetate, did little to promote appetite or weight gain in patients with advanced cancer. </Para></SummarySection><SummarySection id="_84"><Title><ScientificName>Cannabis</ScientificName></Title><Para id="_78">In trials conducted in the 1980s that involved <GlossaryTermRef href="CDR0000561403" dictionary="Cancer.gov" audience="Patient">healthy control</GlossaryTermRef> subjects, inhaling <ScientificName>Cannabis</ScientificName> led to an increase in <GlossaryTermRef href="CDR0000044109" dictionary="Cancer.gov" audience="Patient">caloric intake</GlossaryTermRef>, mainly in the form of between-meal snacks, with increased intakes of fatty and sweet foods.<Reference refidx="56"/><Reference refidx="57"/> </Para><Para id="_316">Despite patients' great interest in oral preparations of <ScientificName>Cannabis</ScientificName> to improve appetite, there is only one trial of <ScientificName>Cannabis</ScientificName> extract used for appetite stimulation. In an RCT, researchers compared the safety and effectiveness of orally administered <ScientificName>Cannabis</ScientificName> extract (2.5 mg THC and 1 mg CBD), THC (2.5 mg), or placebo for the treatment of cancer-related anorexia-cachexia. A total of 243 patients with advanced cancer received treatment twice daily for 6 weeks.  While all extracts were well tolerated, no differences were observed in patients' appetite or quality of life among the three groups at this dose level and duration of <GlossaryTermRef href="CDR0000454757" dictionary="Cancer.gov" audience="Patient">intervention</GlossaryTermRef>.<Reference refidx="58"/></Para><Para id="_237">No published studies have explored the effect of inhaled <ScientificName>Cannabis</ScientificName> on appetite in patients with cancer.</Para></SummarySection></SummarySection><SummarySection id="_51"><Title>Analgesia</Title><SummarySection id="_85"><Title>Cannabinoids</Title><Para id="_52">Pain management improves a patient’s quality of life throughout all stages of cancer.  Through the study of cannabinoid <GlossaryTermRef href="CDR0000044958" dictionary="Cancer.gov" audience="Patient">receptors</GlossaryTermRef>, endocannabinoids, and synthetic agonists and antagonists, the mechanisms of cannabinoid-induced <GlossaryTermRef href="CDR0000449929" dictionary="Cancer.gov" audience="Patient">analgesia</GlossaryTermRef> have been analyzed.<Reference refidx="59"/>[<LOERef href="CDR0000335121" dictionary="NotSet" audience="Health professional">Level of evidence: 1iC</LOERef>]  The CB1 receptor is found in the <GlossaryTermRef href="CDR0000046481" dictionary="Cancer.gov" audience="Patient">central nervous system</GlossaryTermRef> (CNS) and in peripheral <GlossaryTermRef href="CDR0000373935" dictionary="Cancer.gov" audience="Patient">nerve</GlossaryTermRef> terminals.<Reference refidx="60"/> CB2 receptors are located mainly in peripheral <GlossaryTermRef href="CDR0000046683" dictionary="Cancer.gov" audience="Patient">tissue</GlossaryTermRef> and are expressed in only low amounts in the CNS.  Whereas only CB1 agonists exert <GlossaryTermRef href="CDR0000045590" dictionary="Cancer.gov" audience="Patient">analgesic</GlossaryTermRef> activity in the CNS, both CB1 and CB2 agonists have analgesic activity in peripheral tissue.<Reference refidx="61"/><Reference refidx="62"/></Para><Para id="_53">Cancer pain results from <GlossaryTermRef href="CDR0000044042" dictionary="Cancer.gov" audience="Patient">inflammation</GlossaryTermRef>, invasion of bone or other pain-sensitive structures, or nerve injury.  When cancer pain is severe and persistent, it is often resistant to treatment with <GlossaryTermRef href="CDR0000045054" dictionary="Cancer.gov" audience="Patient">opioids</GlossaryTermRef>.</Para><Para id="_54">Two studies examined the effects of oral delta-9-THC on cancer pain.  The first, a double-blind, placebo-controlled study involving ten patients, measured both pain intensity and pain relief.<Reference refidx="63"/> It was reported that 15 mg and 20 mg doses of the cannabinoid delta-9-THC were associated with substantial analgesic effects,  with antiemetic effects and  appetite stimulation.</Para><Para id="_55">In a <GlossaryTermRef href="CDR0000044671" dictionary="Cancer.gov" audience="Patient">follow-up</GlossaryTermRef>, single-dose study involving 36 patients, 10 mg of delta-9-THC produced analgesic effects during a 7-hour <GlossaryTermRef href="CDR0000045981" dictionary="Cancer.gov" audience="Patient">observation</GlossaryTermRef> period that were comparable to 60 mg doses of codeine, and  20 mg doses of delta-9-THC induced effects equivalent to 120 mg doses of codeine.<Reference refidx="64"/> Higher doses of THC were found to be more sedating than codeine.</Para><Para id="_56">Another study examined the effects of a  plant extract with controlled cannabinoid content in an oromucosal spray.  In a multicenter, double-blind, placebo-controlled study, the THC:CBD nabiximols extract  and THC extract alone were compared in the analgesic management of patients with advanced cancer  and with moderate-to-severe cancer-related pain.  Patients were assigned to one of three treatment groups: THC:CBD extract, THC extract, or placebo.  The researchers concluded that the THC:CBD extract was efficacious for pain relief in patients with advanced cancer whose pain was not fully relieved by strong opioids.<Reference refidx="65"/> In a randomized, placebo-controlled, graded-dose trial, opioid-treated patients with cancer with poorly controlled <GlossaryTermRef href="CDR0000044654" dictionary="Cancer.gov" audience="Patient">chronic pain</GlossaryTermRef> demonstrated significantly better control of pain and sleep disruption with THC:CBD oromucosal spray at lower doses (1–4 and 6–10 sprays/d), compared with placebo. Adverse events were dose related, with  only the high-dose group (11–16 sprays/d) comparing unfavorably with the placebo arm. These studies provide promising evidence of an <Emphasis>adjuvant analgesic</Emphasis> effect of  THC:CBD in this opioid-refractory patient population and may provide an opportunity to address this significant clinical challenge.<Reference refidx="66"/> An open-label extension study of 43 patients who had participated in the randomized trial found that some patients continued to obtain relief of their cancer-related pain with long-term use of the THC:CBD oromucosal spray without increasing their dose of the spray or the dose of their other analgesics.<Reference refidx="67"/></Para><Para id="_57">An <GlossaryTermRef href="CDR0000286105" dictionary="Cancer.gov" audience="Patient">observational study</GlossaryTermRef> assessed the effectiveness of nabilone in patients with advanced cancer who were experiencing pain and other <GlossaryTermRef href="CDR0000045022" dictionary="Cancer.gov" audience="Patient">symptoms</GlossaryTermRef> (anorexia, depression, and anxiety).  The researchers reported  that patients who used nabilone experienced improved management of pain, nausea, anxiety, and <GlossaryTermRef href="CDR0000454701" dictionary="Cancer.gov" audience="Patient">distress</GlossaryTermRef> when compared with untreated patients.  Nabilone was also associated with a decreased use of opioids, <GlossaryTermRef href="CDR0000044481" dictionary="Cancer.gov" audience="Patient">nonsteroidal anti-inflammatory drugs</GlossaryTermRef>, tricyclic <GlossaryTermRef href="CDR0000044105" dictionary="Cancer.gov" audience="Patient">antidepressants</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045039" dictionary="Cancer.gov" audience="Patient">gabapentin</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045262" dictionary="Cancer.gov" audience="Patient">dexamethasone</GlossaryTermRef>, metoclopramide, and ondansetron.<Reference refidx="68"/></Para></SummarySection><SummarySection id="_86"><Title><ScientificName>Cannabis</ScientificName></Title><Para id="_157"><GlossaryTermRef href="CDR0000454774" dictionary="Cancer.gov" audience="Patient">Animal studies</GlossaryTermRef> have suggested a <GlossaryTermRef href="CDR0000330184" dictionary="Cancer.gov" audience="Patient">synergistic</GlossaryTermRef> analgesic effect when cannabinoids are combined with opioids. The results from one pharmacokinetic interaction study have been reported.  In this study, 21 patients with chronic pain were administered <GlossaryTermRef href="CDR0000796901" dictionary="Cancer.gov" audience="Patient">vaporized</GlossaryTermRef> <ScientificName>Cannabis</ScientificName> along with sustained-release <GlossaryTermRef href="CDR0000045400" dictionary="Cancer.gov" audience="Patient">morphine</GlossaryTermRef> or <GlossaryTermRef href="CDR0000454764" dictionary="Cancer.gov" audience="Patient">oxycodone</GlossaryTermRef> for 5 days.<Reference refidx="69"/> The patients who received vaporized <ScientificName>Cannabis</ScientificName> and sustained-release morphine had a statistically significant decrease in their <GlossaryTermRef href="CDR0000285973" dictionary="Cancer.gov" audience="Patient">mean</GlossaryTermRef> pain score over the 5-day period; those who received vaporized <ScientificName>Cannabis</ScientificName> and oxycodone did not. These findings should be verified by further studies before recommendations favoring such an approach are warranted in general clinical practice.</Para><Para id="_192">Patients with cancer may experience neuropathic pain, especially if treated with <GlossaryTermRef href="CDR0000045841" dictionary="Cancer.gov" audience="Patient">platinum-based</GlossaryTermRef> chemotherapy or <GlossaryTermRef href="CDR0000046138" dictionary="Cancer.gov" audience="Patient">taxanes</GlossaryTermRef>. Two RCTs of inhaled <ScientificName>Cannabis</ScientificName>  in patients with <GlossaryTermRef href="CDR0000044705" dictionary="Cancer.gov" audience="Patient">peripheral neuropathy</GlossaryTermRef> or neuropathic pain of various etiologies found  that pain was reduced in patients who received inhaled <ScientificName>Cannabis</ScientificName>, compared with those who received placebo.<Reference refidx="70"/><Reference refidx="71"/> A retrospective analysis examined the effect of <ScientificName>Cannabis</ScientificName> on chemotherapy-induced peripheral neuropathy (CIPN) in Israeli patients with cancer who received <GlossaryTermRef href="CDR0000045465" dictionary="Cancer.gov" audience="Patient">oxaliplatin</GlossaryTermRef>-based regimens for <GlossaryTermRef href="CDR0000045692" dictionary="Cancer.gov" audience="Patient">gastrointestinal</GlossaryTermRef> malignancies.<Reference refidx="72"/>[<LOERef href="CDR0000335137" dictionary="NotSet" audience="Health professional">Level of evidence: 2Diii</LOERef>]  Patients were divided into three groups on the basis of their exposure to <ScientificName>Cannabis</ScientificName>: <ScientificName>Cannabis</ScientificName>-first group (received <ScientificName>Cannabis</ScientificName> before starting oxaliplatin), oxaliplatin-first group (received oxaliplatin before starting <ScientificName>Cannabis</ScientificName>), and controls (no <ScientificName>Cannabis</ScientificName> use).  A significant difference in grade 2 to 3 CIPN was seen between the <ScientificName>Cannabis</ScientificName>-exposed patients (15.3%) and controls (27.9%) (<Emphasis>P</Emphasis> &lt; .001). The neuropathy-sparing effect was more pronounced among those treated with <ScientificName>Cannabis</ScientificName> first (75%) compared with those who received oxaliplatin first (46.2%) (<Emphasis>P</Emphasis> &lt; .001). Some limitations of this study were its retrospective design and documentation of <ScientificName>Cannabis</ScientificName> use as qualitative, not quantitative.</Para><Para id="_317">A randomized, placebo-controlled, crossover, pilot study of nabiximols in 16 patients with chemotherapy-induced neuropathic pain showed no significant difference between the treatment and placebo groups. A responder analysis, however,  demonstrated that five patients reported a reduction in their pain of at least 2 points on an 11-point scale, suggesting that a larger follow-up study may be warranted.<Reference refidx="73"/></Para><Para id="_364">One real-world randomized controlled trial explored <ScientificName>Cannabis</ScientificName> use in patients with advanced cancer who  received care in a community <GlossaryTermRef href="CDR0000045434" dictionary="Cancer.gov" audience="Patient">oncology</GlossaryTermRef> practice setting (148 screened; 30 randomly assigned; 18 analyzed).<Reference refidx="74"/> Once certified by their <GlossaryTermRef href="CDR0000046260" dictionary="Cancer.gov" audience="Patient">oncologists</GlossaryTermRef>, participants were randomly assigned to receive early <ScientificName>Cannabis</ScientificName> (EC) or delayed start of medical <ScientificName>Cannabis</ScientificName> (DC) for 3 months as part of a state-sponsored <ScientificName>Cannabis</ScientificName> program. The EC group had stable opioid usage compared with the DC group who had an increase in opioid usage during the 3-month study period. Overall, there were no significant changes in quality of life or symptom scores between the  groups, with  no overall <ScientificName>Cannabis</ScientificName>-related adverse events. Limitations included a variety of cancer types and no consistent use of <ScientificName>Cannabis</ScientificName> products (108 different <ScientificName>Cannabis</ScientificName> products were dispensed during the study period).</Para></SummarySection></SummarySection><SummarySection id="_60"><Title>Anxiety and Sleep</Title><SummarySection id="_240"><Title>Cannabinoids</Title><Para id="_241">In a small pilot study of analgesia involving ten patients with cancer pain, secondary measures showed that 15 mg and 20 mg doses of the cannabinoid delta-9-THC were associated with <GlossaryTermRef href="CDR0000044645" dictionary="Cancer.gov" audience="Patient">anxiolytic</GlossaryTermRef> effects.<Reference refidx="63"/>[<LOERef href="CDR0000335121" dictionary="NotSet" audience="Health professional">Level of evidence: 1iC</LOERef>]</Para><Para id="_243">A small placebo-controlled study of dronabinol in patients with cancer with <GlossaryTermRef href="CDR0000044643" dictionary="Cancer.gov" audience="Patient">altered</GlossaryTermRef> chemosensory perception also noted increased quality of sleep and relaxation in THC-treated patients.<Reference refidx="53"/>[<LOERef href="CDR0000335121" dictionary="NotSet" audience="Health professional">Level of evidence: 1iC</LOERef>]</Para></SummarySection><SummarySection id="_87"><Title><ScientificName>Cannabis</ScientificName></Title><Para id="_61">Patients often experience mood elevation after exposure to <ScientificName>Cannabis</ScientificName>, depending on their previous experience. In a five-patient <GlossaryTermRef href="CDR0000044006" dictionary="Cancer.gov" audience="Patient">case series</GlossaryTermRef> of inhaled <ScientificName>Cannabis</ScientificName> that examined analgesic effects in chronic pain, it was reported that patients who self-administered <ScientificName>Cannabis</ScientificName> had improved mood, improved sense of well-being, and less anxiety.<Reference refidx="75"/></Para><Para id="_62">Another common effect of <ScientificName>Cannabis</ScientificName> is sleepiness.  A small placebo-controlled study of dronabinol in patients with cancer with altered chemosensory perception also noted increased quality of sleep and relaxation in  THC-treated patients.<Reference refidx="53"/></Para><Para id="_301">Seventy-four patients with newly <GlossaryTermRef href="CDR0000046450" dictionary="Cancer.gov" audience="Patient">diagnosed</GlossaryTermRef> head and neck cancer self-described as current <ScientificName>Cannabis</ScientificName> users were matched to 74 nonusers in a Canadian study investigating quality of life using the EuroQol-5D and Edmonton Symptom Assessment System instruments.<Reference refidx="76"/> <ScientificName>Cannabis</ScientificName> users had significantly lower scores in the anxiety/depression (difference, 0.74; 95% CI, 0.557–0.930) and pain/discomfort (difference, 0.29; 95% CI, 0.037–1.541) domains. <ScientificName>Cannabis</ScientificName> users were also less tired, had more appetite, and better general well-being.</Para><Para id="_365">A single center, <GlossaryTermRef href="CDR0000045831" dictionary="Cancer.gov" audience="Patient">phase II</GlossaryTermRef>, double-blind study of two ratios (1:1 [THC:CBD] and 4:1 [THC:CBD])  of an oral medical <ScientificName>Cannabis</ScientificName> oil enrolled patients with recurrent or <GlossaryTermRef href="CDR0000285970" dictionary="Cancer.gov" audience="Patient">inoperable</GlossaryTermRef> <GlossaryTermRef href="CDR0000386205" dictionary="Cancer.gov" audience="Patient">high-grade</GlossaryTermRef> <GlossaryTermRef href="CDR0000045700" dictionary="Cancer.gov" audience="Patient">glioma</GlossaryTermRef>. Investigators assessed the side effects and Functional Assessment of Cancer Therapy-Brain (FACT-Br) at baseline and 12 weeks as a <GlossaryTermRef href="CDR0000044163" dictionary="Cancer.gov" audience="Patient">primary outcome</GlossaryTermRef>.<Reference refidx="77"/>  There was no difference in the primary end point; however, some significant differences were noted in the subscores of the FACT-Br (i.e., physical, functional, and sleep favored the 1:1 ratio) and these end points would be appropriate for future research.</Para></SummarySection></SummarySection><SummarySection id="_377"><Title>Symptom Management With Cannabidiol</Title><Para id="_378">A randomized, double-blind, placebo-controlled trial (n = 144) assessed the impact of oral cannabidiol oil (50–200 mg three times a day) on the total symptom distress score (TSDS), a measure of overall cancer symptom burden.<Reference refidx="78"/> All patients received baseline care from <GlossaryTermRef href="CDR0000269448" dictionary="Cancer.gov" audience="Patient">palliative care</GlossaryTermRef> <GlossaryTermRef href="CDR0000478785" dictionary="Cancer.gov" audience="Patient">specialists</GlossaryTermRef>. No significant difference was found in the <GlossaryTermRef href="CDR0000044941" dictionary="Cancer.gov" audience="Patient">median</GlossaryTermRef> TSDS between the two arms at the two assessment points (day 14 and day 28). This study had several limitations, including heterogeneity of the patient population, low symptom burden of patients at baseline, and a high level of patient withdrawals from both study arms.</Para></SummarySection><SummarySection id="_379"><Title>Pediatric Population and Cannabis and Cannabinoid Medicinal Use</Title><Para id="_380"> A growing number of pediatric patients are seeking symptom relief with <ScientificName>Cannabis</ScientificName> or cannabinoid treatment, although studies are limited.<Reference refidx="79"/> The <ExternalRef xref="https://www.aap.org/">American Academy of Pediatrics</ExternalRef> has not endorsed <ScientificName>Cannabis</ScientificName> and cannabinoid use because of concerns about brain development.</Para><Para id="_381">A <GlossaryTermRef href="CDR0000044956" dictionary="Cancer.gov" audience="Patient">retrospective study</GlossaryTermRef> from Israel of 50 pediatric oncology patients who were <GlossaryTermRef href="CDR0000044711" dictionary="Cancer.gov" audience="Patient">prescribed</GlossaryTermRef> medicinal <ScientificName>Cannabis</ScientificName> over an 8-year period  reported that the most common indications included the following:<Reference refidx="80"/></Para><ItemizedList id="_382" Style="bullet">
     <ListItem>Nausea and vomiting.</ListItem><ListItem>Depressed mood.</ListItem><ListItem>Sleep disturbances.</ListItem><ListItem>Poor appetite and weight loss.</ListItem><ListItem>Pain.</ListItem></ItemizedList><Para id="_383">Most of the patients (n = 30) received <ScientificName>Cannabis</ScientificName> in the form of oral oil drops, with some of the older children inhaling vaporized <ScientificName>Cannabis</ScientificName> or combining inhalation with oral oils. Structured interviews with the parents, and their child when appropriate, revealed that 40 participants (80%) reported a high level of general satisfaction with the use of <ScientificName>Cannabis</ScientificName>  with infrequent short-term side effects.<Reference refidx="80"/> Survey studies revealed that most responding pediatricians   in the United States and Canada supported the use of medical <ScientificName>Cannabis</ScientificName> for symptom management in pediatric patients with cancer.<Reference refidx="81"/><Reference refidx="82"/></Para></SummarySection><SummarySection id="_256"><Title>Clinical Studies of <ScientificName>Cannabis</ScientificName> and Cannabinoids</Title><Table id="_245"><Title>Table 2.  Clinical Studies of <ScientificName>Cannabis</ScientificName><Superscript>a</Superscript></Title><TGroup Cols="7"><ColSpec ColName="col1" ColNum="1" ColWidth="13.72%"/><ColSpec ColName="col2" ColNum="2" ColWidth="13.45%"/><ColSpec ColName="col3" ColNum="3" ColWidth="14.67%"/><ColSpec ColName="col4" ColNum="4" ColWidth="14.26%"/><ColSpec ColName="col5" ColNum="5" ColWidth="13.86%"/><ColSpec ColName="col6" ColNum="6" ColWidth="14.40%"/><ColSpec ColName="col7" ColNum="7" ColWidth="15.61%"/><THead><Row><entry>Reference </entry><entry>Trial Design</entry><entry>Condition or Cancer Type </entry><entry>Treatment Groups (Enrolled; Treated; Placebo or No Treatment Control)<Superscript>b</Superscript> </entry><entry>Results<Superscript>c</Superscript> </entry><entry><GlossaryTermRef href="CDR0000044011" dictionary="Cancer.gov" audience="Patient">Concurrent Therapy</GlossaryTermRef> Used<Superscript>d</Superscript> </entry><entry>Level of Evidence Score<Superscript>e</Superscript> </entry></Row></THead><TFoot><Row><entry NameEnd="col7" NameSt="col1">5-HT3 = 5-hydroxytryptamine 3; CINV = chemotherapy-induced nausea and vomiting; N/V = nausea and vomiting; RCT = randomized controlled trial.</entry></Row><Row><entry NameEnd="col7" NameSt="col1"><Superscript>a</Superscript>For additional information and definition of terms, see text and  the <ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-terms/">NCI Dictionary of Cancer Terms</ExternalRef>.</entry></Row><Row><entry NameEnd="col7" NameSt="col1"><Superscript>b</Superscript>Number of patients treated plus number of patient controls may not equal number of patients enrolled; number of patients enrolled equals number of patients initially recruited/considered by the researchers who conducted a study; number of patients treated equals number of enrolled patients who were given the treatment being studied AND for whom results were reported.</entry></Row><Row><entry NameEnd="col7" NameSt="col1"><Superscript>c</Superscript>Strongest evidence reported that the treatment under study has activity or otherwise improves the well-being of patients with cancer.</entry></Row><Row><entry NameEnd="col7" NameSt="col1"><Superscript>d</Superscript>Concurrent therapy for symptoms treated (not cancer).</entry></Row><Row><entry NameEnd="col7" NameSt="col1"><Superscript>e</Superscript>For information about <GlossaryTermRef href="CDR0000446533" dictionary="Cancer.gov" audience="Patient">levels of evidence</GlossaryTermRef> analysis and scores, see <SummaryRef href="CDR0000256874" url="/publications/pdq/levels-evidence/cam">Levels of Evidence for Human Studies of Integrative, Alternative, and Complementary Therapies</SummaryRef>.</entry></Row></TFoot><TBody><Row><entry><Reference refidx="77"/></entry><entry>RCT</entry><entry>High-grade gliomas</entry><entry>88; 45 (1:1), 43 (4:1); None</entry><entry>No difference in the primary end point</entry><entry>Dexamethasone, temozolomide, <GlossaryTermRef href="CDR0000046115" dictionary="Cancer.gov" audience="Patient">bevacizumab</GlossaryTermRef>, <GlossaryTermRef href="CDR0000046017" dictionary="Cancer.gov" audience="Patient">lomustine</GlossaryTermRef></entry><entry><LOERef href="CDR0000335121" dictionary="NotSet" audience="Health professional">1iC</LOERef></entry></Row><Row><entry><Reference refidx="46"/></entry><entry>RCT</entry><entry>CINV</entry><entry>8; 8; None</entry><entry>No antiemetic effect reported</entry><entry>No</entry><entry><LOERef href="CDR0000335121" dictionary="NotSet" audience="Health professional">1iC</LOERef></entry></Row><Row><entry><Reference refidx="47"/></entry><entry>RCT</entry><entry>CINV</entry><entry>15; 15; None</entry><entry>Decreased N/V</entry><entry>No</entry><entry><LOERef href="CDR0000335127" dictionary="NotSet" audience="Health professional">1iiC</LOERef></entry></Row><Row><entry><Reference refidx="50"/></entry><entry>Pilot RCT</entry><entry>CINV</entry><entry>16; 7; 9</entry><entry>Decreased delayed N/V</entry><entry>5-HT3 receptor antagonists</entry><entry><LOERef href="CDR0000335121" dictionary="NotSet" audience="Health professional">1iC</LOERef></entry></Row><Row><entry><Reference refidx="69"/></entry><entry>Nonrandomized trial</entry><entry>Chronic pain</entry><entry>21;10 (morphine), 11 (oxycodone); None</entry><entry>Decreased pain</entry><entry>Yes, morphine, oxycodone</entry><entry><LOERef href="CDR0000335134" dictionary="NotSet" audience="Health professional">2C</LOERef></entry></Row><Row><entry><Reference refidx="76"/></entry><entry>Prospective cohort study</entry><entry>Anxiety, pain, depression, loss of appetite</entry><entry>148; 74; 74</entry><entry>Decreased pain, anxiety, depression, increased appetite</entry><entry>Unknown</entry><entry><LOERef href="CDR0000335134" dictionary="NotSet" audience="Health professional">2C</LOERef></entry></Row></TBody></TGroup></Table><Table id="_246"><Title>Table 3.  Clinical Studies of Cannabinoids<Superscript>a</Superscript></Title><TGroup Cols="7"><ColSpec ColName="col1" ColNum="1" ColWidth="18.34%"/><ColSpec ColName="col2" ColNum="2" ColWidth="10.24%"/><ColSpec ColName="col3" ColNum="3" ColWidth="14.24%"/><ColSpec ColName="col4" ColNum="4" ColWidth="14.15%"/><ColSpec ColName="col5" ColNum="5" ColWidth="14.15%"/><ColSpec ColName="col6" ColNum="6" ColWidth="19.94%"/><ColSpec ColName="col7" ColNum="7" ColWidth="8.90%"/><THead><Row><entry>Reference </entry><entry>Trial Design</entry><entry>Condition or Cancer Type </entry><entry>Treatment Groups (Enrolled; Treated; Placebo or No Treatment Control)<Superscript>b</Superscript> </entry><entry>Results<Superscript>c</Superscript> </entry><entry>Concurrent Therapy Used<Superscript>d</Superscript> </entry><entry>Level of Evidence Score<Superscript>e</Superscript> </entry></Row></THead><TFoot><Row><entry NameEnd="col7" NameSt="col1">CBD = cannabidiol; No. = number; NSAIDs = nonsteroidal anti-inflammatory drugs; QoL = quality of life; RCT = randomized controlled trial; THC = delta-9-tetrahydrocannabinol.</entry></Row><Row><entry NameEnd="col7" NameSt="col1"><Superscript>a</Superscript>For additional information and definition of terms, see text and the <ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-terms/">NCI Dictionary of Cancer Terms</ExternalRef>.</entry></Row><Row><entry NameEnd="col7" NameSt="col1"><Superscript>b</Superscript>Number of patients treated plus number of patient controls may not equal number of patients enrolled; number of patients enrolled equals number of patients initially recruited/considered by the researchers who conducted a study; number of patients treated equals number of enrolled patients who were given the treatment being studied AND for whom results were reported.</entry></Row><Row><entry NameEnd="col7" NameSt="col1"><Superscript>c</Superscript>Strongest evidence reported that the treatment under study has activity or otherwise improves the well-being of patients with cancer.</entry></Row><Row><entry NameEnd="col7" NameSt="col1"><Superscript>d</Superscript>Concurrent therapy for symptoms treated (not cancer).</entry></Row><Row><entry NameEnd="col7" NameSt="col1"><Superscript>e</Superscript>For information about levels of evidence analysis and scores, see <SummaryRef href="CDR0000256874" url="/publications/pdq/levels-evidence/cam">Levels of Evidence for Human Studies of Integrative, Alternative, and Complementary Therapies</SummaryRef>.</entry></Row></TFoot><TBody><Row><entry><Reference refidx="55"/></entry><entry>RCT</entry><entry>Cancer-associated anorexia</entry><entry>469;  dronabinol 152, megestrol acetate 159, or both 158; None</entry><entry>Megestrol acetate provided increased appetite and weight gain,  among patients with advanced cancer compared with dronabinol alone</entry><entry>No</entry><entry><LOERef href="CDR0000335121" dictionary="NotSet" audience="Health professional">1iC</LOERef></entry></Row><Row><entry><Reference refidx="53"/></entry><entry>Pilot RCT</entry><entry>Appetite</entry><entry>21; 11; 10</entry><entry>THC, compared with placebo, improved and enhanced taste and smell</entry><entry>No</entry><entry><LOERef href="CDR0000335121" dictionary="NotSet" audience="Health professional">1iC</LOERef></entry></Row><Row><entry><Reference refidx="58"/></entry><entry>RCT</entry><entry>Cancer-related anorexia-cachexia syndrome</entry><entry>243; <ScientificName>Cannabis</ScientificName> extract 95, THC 100; 48</entry><entry>No differences in patients’ appetite or QoL were found</entry><entry>No</entry><entry><LOERef href="CDR0000335121" dictionary="NotSet" audience="Health professional">1iC</LOERef><GlossaryTermRef href="CDR0000335121" dictionary="NotSet" audience="Health professional"/></entry></Row><Row><entry><Reference refidx="83"/></entry><entry>RCT</entry><entry>Appetite</entry><entry>139; 72; 67</entry><entry>Increase in appetite</entry><entry>No</entry><entry><LOERef href="CDR0000335121" dictionary="NotSet" audience="Health professional">1iC</LOERef></entry></Row><Row><entry><Reference refidx="54"/></entry><entry>RCT</entry><entry>Anorexia</entry><entry>47; 22; 25</entry><entry>Increased calorie intake</entry><entry>No</entry><entry><LOERef href="CDR0000335121" dictionary="NotSet" audience="Health professional">1iC</LOERef></entry></Row><Row><entry><Reference refidx="63"/></entry><entry>RCT</entry><entry>Pain</entry><entry>10; 10; None</entry><entry>Pain relief</entry><entry>No</entry><entry><LOERef href="CDR0000335121" dictionary="NotSet" audience="Health professional">1iC</LOERef></entry></Row><Row><entry><Reference refidx="65"/></entry><entry>RCT</entry><entry>Pain</entry><entry>177; 60 (THC:CBD), 58 (THC); 59</entry><entry>THC:CBD extract group had reduced pain</entry><entry>Yes, opioids</entry><entry><LOERef href="CDR0000335121" dictionary="NotSet" audience="Health professional">1iC</LOERef></entry></Row><Row><entry><Reference refidx="66"/></entry><entry>RCT</entry><entry>Pain</entry><entry>360; 269; 91</entry><entry>Decreased pain in low-dose group</entry><entry>Yes, opioids</entry><entry><LOERef href="CDR0000335121" dictionary="NotSet" audience="Health professional">1iC</LOERef></entry></Row><Row><entry><Reference refidx="67"/></entry><entry>Open-label extension</entry><entry>Pain</entry><entry>43; 39 (THC:CBD), 4 (THC), None</entry><entry>Decreased pain</entry><entry>Yes, opioids</entry><entry><LOERef href="CDR0000335134" dictionary="NotSet" audience="Health professional">2C</LOERef></entry></Row><Row><entry><Reference refidx="68"/></entry><entry>Observational study</entry><entry>Pain</entry><entry>112; 47; 65</entry><entry>Decreased pain</entry><entry>Yes, opioids, <GlossaryTermRef href="CDR0000045807" dictionary="Cancer.gov" audience="Patient">NSAIDs</GlossaryTermRef>, gabapentin</entry><entry><LOERef href="CDR0000335134" dictionary="NotSet" audience="Health professional">2C</LOERef></entry></Row></TBody></TGroup></Table></SummarySection><SummarySection id="_TrialSearch_9_sid_5"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_9_22">Use our <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search/advanced">advanced clinical trial search</ExternalRef> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">General information</ExternalRef> about clinical trials is also available.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="8972919">Adams IB, Martin BR: Cannabis: pharmacology and toxicology in animals and humans. Addiction 91 (11): 1585-614, 1996.</Citation><Citation idx="2" PMID="3012605">Agurell S, Halldin M, Lindgren JE, et al.: Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev 38 (1): 21-43, 1986.</Citation><Citation idx="3" PMID="7584607">Yamamoto I, Watanabe K, Narimatsu S, et al.: Recent advances in the metabolism of cannabinoids. Int J Biochem Cell Biol 27 (8): 741-6, 1995.</Citation><Citation idx="4" PMID="17405893">Engels FK, de Jong FA, Sparreboom A, et al.: Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel. Oncologist 12 (3): 291-300, 2007.</Citation><Citation idx="5">FDA Warns Companies Marketing Unproven Products, Derived From Marijuana, That Claim to Treat or Cure Cancer
[News Release]. Silver Spring, Md: Food and Drug Administration, 2017. <ExternalRef xref="https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm583295.htm">Available online</ExternalRef>. Last accessed January 4, 2019.</Citation><Citation idx="6" PMID="21821735">Yamaori S, Okamoto Y, Yamamoto I, et al.: Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos 39 (11): 2049-56, 2011.</Citation><Citation idx="7" PMID="23318708">Jiang R, Yamaori S, Okamoto Y, et al.: Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19. Drug Metab Pharmacokinet 28 (4): 332-8, 2013.</Citation><Citation idx="8">Azwell T, Ciotti C, Adams A: Variation among hemp (Cannabis sativus L.) analytical testing laboratories evinces regulatory and quality control issues for the industry. J Appl Res Med Aromat Plants  31: 100434, 2022. <ExternalRef xref="https://doi.org/10.1016/j.jarmap.2022.100434">Available online. </ExternalRef> Last accessed October 17, 2024.</Citation><Citation idx="9" PMID="19057263">Berthiller J, Straif K, Boniol M, et al.: Cannabis smoking and risk of lung cancer in men: a pooled analysis of three studies in Maghreb. J Thorac Oncol 3 (12): 1398-403, 2008.</Citation><Citation idx="10" PMID="9328194">Sidney S, Quesenberry CP, Friedman GD, et al.: Marijuana use and cancer incidence (California, United States). Cancer Causes Control 8 (5): 722-8, 1997.</Citation><Citation idx="11" PMID="17035389">Hashibe M, Morgenstern H, Cui Y, et al.: Marijuana use and the risk of lung and upper aerodigestive tract cancers: results of a population-based case-control study. Cancer Epidemiol Biomarkers Prev 15 (10): 1829-34, 2006.</Citation><Citation idx="12" PMID="16832000">Mehra R, Moore BA, Crothers K, et al.: The association between marijuana smoking and lung cancer: a systematic review. Arch Intern Med 166 (13): 1359-67, 2006.</Citation><Citation idx="13">National Academies of Sciences, Engineering, and Medicine: The Health Effects of Cannabis and Cannabinoids:  The Current State of Evidence and Recommendations for Research. The National Academies Press, 2017.</Citation><Citation idx="14" PMID="24351902">Marks MA, Chaturvedi AK, Kelsey K, et al.: Association of marijuana smoking with oropharyngeal and oral tongue cancers: pooled analysis from the INHANCE consortium. Cancer Epidemiol Biomarkers Prev 23 (1): 160-71, 2014.</Citation><Citation idx="15" PMID="26433192">de Carvalho MF, Dourado MR, Fernandes IB, et al.: Head and neck cancer among marijuana users: a meta-analysis of matched case-control studies. Arch Oral Biol 60 (12): 1750-5, 2015.</Citation><Citation idx="16" PMID="19204904">Daling JR, Doody DR, Sun X, et al.: Association of marijuana use and the incidence of testicular germ cell tumors. Cancer 115 (6): 1215-23, 2009.</Citation><Citation idx="17" PMID="20925043">Trabert B, Sigurdson AJ, Sweeney AM, et al.: Marijuana use and testicular germ cell tumors. Cancer 117 (4): 848-53, 2011.</Citation><Citation idx="18" PMID="22965656">Lacson JC, Carroll JD, Tuazon E, et al.: Population-based case-control study of recreational drug use and testis cancer risk confirms an association between marijuana use and nonseminoma risk. Cancer 118 (21): 5374-83, 2012.</Citation><Citation idx="19" PMID="29093004">Callaghan RC, Allebeck P, Akre O, et al.: Cannabis Use and Incidence of Testicular Cancer: A 42-Year Follow-up of Swedish Men between 1970 and 2011. Cancer Epidemiol Biomarkers Prev 26 (11): 1644-1652, 2017.</Citation><Citation idx="20" PMID="25623697">Thomas AA, Wallner LP, Quinn VP, et al.: Association between cannabis use and the risk of bladder cancer: results from the California Men's Health Study. Urology 85 (2): 388-92, 2015.</Citation><Citation idx="21">Health Canada: Marihuana (Marijuana, Cannabis): Dried Plant for Administration by Ingestion or Other Means. Ottawa, Canada: Health Canada, 2010. <ExternalRef xref="http://www.hc-sc.gc.ca/dhp-mps/marihuana/med/infoprof-eng.php">Available online</ExternalRef>. Last accessed October 18, 2017.</Citation><Citation idx="22" PMID="28944449">Pergam SA, Woodfield MC, Lee CM, et al.: Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational use. Cancer 123 (22): 4488-4497, 2017.</Citation><Citation idx="23" PMID="29482741">Bar-Lev Schleider L, Mechoulam R, Lederman V, et al.: Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer. Eur J Intern Med 49: 37-43, 2018.</Citation><Citation idx="24" PMID="30860938">Anderson SP, Zylla DM, McGriff DM, et al.: Impact of Medical Cannabis on Patient-Reported Symptoms for Patients With Cancer Enrolled in Minnesota's Medical Cannabis Program. J Oncol Pract 15 (4): e338-e345, 2019.</Citation><Citation idx="25" PMID="34636036">Weiss MC, Hibbs JE, Buckley ME, et al.: A Coala-T-Cannabis Survey Study of breast cancer patients' use of cannabis before, during, and after treatment. Cancer 128 (1): 160-168, 2022.</Citation><Citation idx="26" PMID="37382737">McClure EA, Walters KJ, Tomko RL, et al.: Cannabis use prevalence, patterns, and reasons for use among patients with cancer and survivors in a state without legal cannabis access. Support Care Cancer 31 (7): 429, 2023.</Citation><Citation idx="27" PMID="16804518">Guzmán M, Duarte MJ, Blázquez C, et al.: A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer 95 (2): 197-203, 2006.</Citation><Citation idx="28" PMID="22555283">Velasco G, Sánchez C, Guzmán M: Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer 12 (6): 436-44, 2012.</Citation><Citation idx="29" PMID="33623076">Twelves C, Sabel M, Checketts D, et al.: A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma. Br J Cancer 124 (8): 1379-1387, 2021.</Citation><Citation idx="30" PMID="31570484">Likar R, Koestenberger M, Stultschnig M, et al.: Concomitant Treatment of Malignant Brain Tumours With CBD - A Case Series and Review of the Literature. Anticancer Res 39 (10): 5797-5801, 2019.</Citation><Citation idx="31" PMID="26033282">Yeshurun M, Shpilberg O, Herscovici C, et al.: Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study. Biol Blood Marrow Transplant 21 (10): 1770-5, 2015.</Citation><Citation idx="32" PMID="24474921">Singh Y, Bali C: Cannabis extract treatment for terminal acute lymphoblastic leukemia with a Philadelphia chromosome mutation. Case Rep Oncol 6 (3): 585-92, 2013.</Citation><Citation idx="33" PMID="21336992">Foroughi M, Hendson G, Sargent MA, et al.: Spontaneous regression of septum pellucidum/forniceal pilocytic astrocytomas--possible role of Cannabis inhalation. Childs Nerv Syst 27 (4): 671-9, 2011.</Citation><Citation idx="34" PMID="32147080">Goyal S, Kubendran S, Kogan M, et al.: High expectations: The landscape of clinical trials of medical marijuana in oncology. Complement Ther Med 49: 102336, 2020.</Citation><Citation idx="35" PMID="17136871">Sutton IR, Daeninck P: Cannabinoids in the management of intractable chemotherapy-induced nausea and vomiting and cancer-related pain. J Support Oncol 4 (10): 531-5, 2006 Nov-Dec.</Citation><Citation idx="36" PMID="6315040">Ahmedzai S, Carlyle DL, Calder IT, et al.: Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. Br J Cancer 48 (5): 657-63, 1983.</Citation><Citation idx="37" PMID="3035479">Chan HS, Correia JA, MacLeod SM: Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial. Pediatrics 79 (6): 946-52, 1987.</Citation><Citation idx="38" PMID="6299551">Johansson R, Kilkku P, Groenroos M: A double-blind, controlled trial of nabilone vs. prochlorperazine for refractory emesis induced by cancer chemotherapy. Cancer Treat Rev 9 (Suppl B): 25-33, 1982.</Citation><Citation idx="39" PMID="3002167">Niiranen A, Mattson K: A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy. Am J Clin Oncol 8 (4): 336-40, 1985.</Citation><Citation idx="40">National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Antiemesis. Version 1.2021. Plymouth Meeting, Pa: National Comprehensive Cancer Network, 2021. <ExternalRef xref="https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf">Available online with free registration</ExternalRef>. Last accessed August 26, 2021..</Citation><Citation idx="41" PMID="32658626">Hesketh PJ, Kris MG, Basch E, et al.: Antiemetics: ASCO Guideline Update. J Clin Oncol 38 (24): 2782-2797, 2020.</Citation><Citation idx="42" PMID="11440936">Tramèr MR, Carroll D, Campbell FA, et al.: Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 323 (7303): 16-21, 2001.</Citation><Citation idx="43" PMID="16540272">Ben Amar M: Cannabinoids in medicine: A review of their therapeutic potential. J Ethnopharmacol 105 (1-2): 1-25, 2006.</Citation><Citation idx="44" PMID="26561338">Smith LA, Azariah F, Lavender VT, et al.: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database Syst Rev  (11): CD009464, 2015.</Citation><Citation idx="45" PMID="17355735">Meiri E, Jhangiani H, Vredenburgh JJ, et al.: Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin 23 (3): 533-43, 2007.</Citation><Citation idx="46" PMID="6261926">Chang AE, Shiling DJ, Stillman RC, et al.: A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. Cancer 47 (7): 1746-51, 1981.</Citation><Citation idx="47" PMID="293141" MedlineID="80086122">Chang AE, Shiling DJ, Stillman RC, et al.: Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation. Ann Intern Med 91 (6): 819-24, 1979.</Citation><Citation idx="48">Levitt M, Faiman C, Hawks R, et al.: Randomized double blind comparison of delta-9-tetrahydrocannabinol and marijuana as chemotherapy antiemetics. [Abstract] Proceedings of the American Society of Clinical Oncology  3: A-C354, 91, 1984.</Citation><Citation idx="49">Musty RE, Rossi R: Effects of smoked cannabis
and oral delta-9-tetrahydrocannabinol
on nausea and emesis
after cancer chemotherapy:
a review of state clinical trials. Journal of Cannabis Therapeutics  1 (1): 29-56, 2001. <ExternalRef xref="http://www.cannabis-med.org/data/pdf/2001-01-2.pdf">Also available online</ExternalRef>. Last accessed October 18, 2017.</Citation><Citation idx="50" PMID="21039759">Duran M, Pérez E, Abanades S, et al.: Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br J Clin Pharmacol 70 (5): 656-63, 2010.</Citation><Citation idx="51" PMID="39151115">Grimison P, Mersiades A, Kirby A, et al.: Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial. J Clin Oncol 42 (34): 4040-4050, 2024.</Citation><Citation idx="52">Regelson W, Butler JR, Schulz J, et al.: Delta-9-tetrahydrocannabinol  as  an  effective  antidepressant  and appetite-stimulating agent in advanced cancer patients. In: Braude MC, Szara S: The  Pharmacology  of  Marihuana. Raven Press, 1976, pp  763-76.</Citation><Citation idx="53" PMID="21343383">Brisbois TD, de Kock IH, Watanabe SM, et al.: Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Ann Oncol 22 (9): 2086-93, 2011.</Citation><Citation idx="54" PMID="29550881">Turcott JG, Del Rocío Guillen Núñez M, Flores-Estrada D, et al.: The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer 26 (9): 3029-3038, 2018.</Citation><Citation idx="55" PMID="11786587" MedlineID="21646473">Jatoi A, Windschitl HE, Loprinzi CL, et al.: Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 20 (2): 567-73, 2002.</Citation><Citation idx="56" PMID="3774823">Foltin RW, Brady JV, Fischman MW: Behavioral analysis of marijuana effects on food intake in humans. Pharmacol Biochem Behav 25 (3): 577-82, 1986.</Citation><Citation idx="57" PMID="3228283">Foltin RW, Fischman MW, Byrne MF: Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory. Appetite 11 (1): 1-14, 1988.</Citation><Citation idx="58" PMID="16849753">Strasser F, Luftner D, Possinger K, et al.: Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol 24 (21): 3394-400, 2006.</Citation><Citation idx="59" PMID="22367503">Aggarwal SK: Cannabinergic pain medicine: a concise clinical primer and survey of randomized-controlled trial results. Clin J Pain 29 (2): 162-71, 2013.</Citation><Citation idx="60" PMID="10462067">Walker JM, Hohmann AG, Martin WJ, et al.: The neurobiology of cannabinoid analgesia. Life Sci 65 (6-7): 665-73, 1999.</Citation><Citation idx="61" PMID="9685157">Calignano A, La Rana G, Giuffrida A, et al.: Control of pain initiation by endogenous cannabinoids. Nature 394 (6690): 277-81, 1998.</Citation><Citation idx="62" PMID="9734389">Fields HL, Meng ID: Watching the pot boil. Nat Med 4 (9): 1008-9, 1998.</Citation><Citation idx="63" PMID="1091664">Noyes R, Brunk SF, Baram DA, et al.: Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol 15 (2-3): 139-43, 1975 Feb-Mar.</Citation><Citation idx="64" PMID="50159">Noyes R, Brunk SF, Avery DA, et al.: The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther 18 (1): 84-9, 1975.</Citation><Citation idx="65" PMID="19896326">Johnson JR, Burnell-Nugent M, Lossignol D, et al.: Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage 39 (2): 167-79, 2010.</Citation><Citation idx="66" PMID="22483680">Portenoy RK, Ganae-Motan ED, Allende S, et al.: Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain 13 (5): 438-49, 2012.</Citation><Citation idx="67" PMID="23141881">Johnson JR, Lossignol D, Burnell-Nugent M, et al.: An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J Pain Symptom Manage 46 (2): 207-18, 2013.</Citation><Citation idx="68" PMID="18402303">Maida V, Ennis M, Irani S, et al.: Adjunctive nabilone in cancer pain and symptom management: a prospective observational study using propensity scoring. J Support Oncol 6 (3): 119-24, 2008.</Citation><Citation idx="69" PMID="22048225">Abrams DI, Couey P, Shade SB, et al.: Cannabinoid-opioid interaction in chronic pain. Clin Pharmacol Ther 90 (6): 844-51, 2011.</Citation><Citation idx="70" PMID="23237736">Wilsey B, Marcotte T, Deutsch R, et al.: Low-dose vaporized cannabis significantly improves neuropathic pain. J Pain 14 (2): 136-48, 2013.</Citation><Citation idx="71" PMID="18403272">Wilsey B, Marcotte T, Tsodikov A, et al.: A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain 9 (6): 506-21, 2008.</Citation><Citation idx="72" PMID="33613702">Waissengrin B, Mirelman D, Pelles S, et al.: Effect of cannabis on oxaliplatin-induced peripheral neuropathy among oncology patients: a retrospective analysis. Ther Adv Med Oncol 13: 1758835921990203, 2021.</Citation><Citation idx="73" PMID="23742737">Lynch ME, Cesar-Rittenberg P, Hohmann AG: A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. J Pain Symptom Manage 47 (1): 166-73, 2014.</Citation><Citation idx="74" PMID="34085149">Zylla DM, Eklund J, Gilmore G, et al.: A randomized trial of medical cannabis in patients with stage IV cancers to assess feasibility, dose requirements, impact on pain and opioid use, safety, and overall patient satisfaction. Support Care Cancer 29 (12): 7471-7478, 2021.</Citation><Citation idx="75" PMID="4426188">Noyes R, Baram DA: Cannabis analgesia. Compr Psychiatry 15 (6): 531-5, 1974 Nov-Dec.</Citation><Citation idx="76" PMID="30073295">Zhang H, Xie M, Archibald SD, et al.: Association of Marijuana Use With Psychosocial and Quality of Life Outcomes Among Patients With Head and Neck Cancer. JAMA Otolaryngol Head Neck Surg 144 (11): 1017-1022, 2018.</Citation><Citation idx="77" PMID="34094937">Schloss J, Lacey J, Sinclair J, et al.: A Phase 2 Randomised Clinical Trial Assessing the Tolerability of Two Different Ratios of Medicinal Cannabis in Patients With High Grade Gliomas. Front Oncol 11: 649555, 2021.</Citation><Citation idx="78" PMID="36409969">Hardy J, Greer R, Huggett G, et al.: Phase IIb Randomized, Placebo-Controlled, Dose-Escalating, Double-Blind Study of Cannabidiol Oil for the Relief of Symptoms in Advanced Cancer (MedCan1-CBD). J Clin Oncol 41 (7): 1444-1452, 2023.</Citation><Citation idx="79" PMID="37635461">Chhabra M, Ben-Eltriki M, Paul A, et al.: Cannabinoids for symptom management in children with cancer: A systematic review and meta-analysis. Cancer 129 (22): 3656-3670, 2023.</Citation><Citation idx="80" PMID="31424297">Ofir R, Bar-Sela G, Weyl Ben-Arush M, et al.: Medical marijuana use for pediatric oncology patients: single institution experience. Pediatr Hematol Oncol 36 (5): 255-266, 2019.</Citation><Citation idx="81" PMID="34672127">Oberoi S, Protudjer JLP, Rapoport A, et al.: Perspectives of pediatric oncologists and palliative care physicians on the therapeutic use of cannabis in children with cancer. Cancer Rep (Hoboken) 5 (9): e1551, 2022.</Citation><Citation idx="82" PMID="29233937">Ananth P, Ma C, Al-Sayegh H, et al.: Provider Perspectives on Use of Medical Marijuana in Children With Cancer. Pediatrics 141 (1): , 2018.</Citation><Citation idx="83" PMID="7730690">Beal JE, Olson R, Laubenstein L, et al.: Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 10 (2): 89-97, 1995.</Citation></ReferenceSection></SummarySection><SummarySection id="_11"><Title>Adverse Effects</Title><SummarySection id="_88"><Title><ScientificName>Cannabis</ScientificName> and Cannabinoids </Title><Para id="_12">Because <GlossaryTermRef href="CDR0000716077" dictionary="Cancer.gov" audience="Patient">cannabinoid</GlossaryTermRef> <GlossaryTermRef href="CDR0000044958" dictionary="Cancer.gov" audience="Patient">receptors</GlossaryTermRef>, unlike <GlossaryTermRef href="CDR0000045054" dictionary="Cancer.gov" audience="Patient">opioid</GlossaryTermRef> receptors, are not located in the brainstem areas controlling respiration, lethal overdoses from <ScientificName><GlossaryTermRef href="CDR0000716285" dictionary="Cancer.gov" audience="Patient">Cannabis</GlossaryTermRef></ScientificName> and cannabinoids do not occur.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/> However, cannabinoid receptors are present in other <GlossaryTermRef href="CDR0000046683" dictionary="Cancer.gov" audience="Patient">tissues</GlossaryTermRef> throughout the body, not just in the <GlossaryTermRef href="CDR0000046481" dictionary="Cancer.gov" audience="Patient">central nervous system</GlossaryTermRef>,  and <GlossaryTermRef href="CDR0000044922" dictionary="Cancer.gov" audience="Patient">adverse effects</GlossaryTermRef> include the following:</Para><ItemizedList id="_338" Style="bullet"><ListItem> <GlossaryTermRef href="CDR0000415551" dictionary="Cancer.gov" audience="Patient">Tachycardia</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000044039" dictionary="Cancer.gov" audience="Patient">Hypotension</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000044197" dictionary="Cancer.gov" audience="Patient">Conjunctival</GlossaryTermRef> injection.</ListItem><ListItem>Bronchodilation.</ListItem><ListItem>Muscle relaxation.</ListItem><ListItem>Decreased <GlossaryTermRef href="CDR0000045692" dictionary="Cancer.gov" audience="Patient">gastrointestinal</GlossaryTermRef> motility.</ListItem></ItemizedList><Para id="_75">Although cannabinoids are considered by some to be addictive <GlossaryTermRef href="CDR0000348921" dictionary="Cancer.gov" audience="Patient">drugs</GlossaryTermRef>, their addictive potential is considerably lower than that of other <GlossaryTermRef href="CDR0000044711" dictionary="Cancer.gov" audience="Patient">prescribed</GlossaryTermRef> agents or substances of abuse.<Reference refidx="2"/><Reference refidx="4"/>  The brain develops a tolerance to cannabinoids.</Para><Para id="_76"><GlossaryTermRef href="CDR0000748333" dictionary="Cancer.gov" audience="Patient">Withdrawal</GlossaryTermRef> <GlossaryTermRef href="CDR0000045022" dictionary="Cancer.gov" audience="Patient">symptoms</GlossaryTermRef> such as irritability, <GlossaryTermRef href="CDR0000044043" dictionary="Cancer.gov" audience="Patient">insomnia</GlossaryTermRef> with sleep <GlossaryTermRef href="CDR0000462676" dictionary="Cancer.gov" audience="Patient">electroencephalogram</GlossaryTermRef> disturbance, restlessness, <GlossaryTermRef href="CDR0000256567" dictionary="Cancer.gov" audience="Patient">hot flashes</GlossaryTermRef>, and, rarely, <GlossaryTermRef href="CDR0000390302" dictionary="Cancer.gov" audience="Patient">nausea</GlossaryTermRef> and cramping have been observed. However, these symptoms appear to be mild compared with  withdrawal symptoms associated with opiates or <GlossaryTermRef href="CDR0000694849" dictionary="Cancer.gov" audience="Patient">benzodiazepines</GlossaryTermRef>, and the symptoms usually dissipate after a few days.</Para><Para id="_77">Unlike other commonly used drugs, cannabinoids are stored in adipose tissue and excreted at a low rate (half-life 1–3 days), so even abrupt cessation of cannabinoid intake is not associated with rapid declines in <GlossaryTermRef href="CDR0000045839" dictionary="Cancer.gov" audience="Patient">plasma</GlossaryTermRef> concentrations that would precipitate  severe or abrupt withdrawal symptoms or drug cravings.</Para><Para id="_294">Cannabidiol  (CBD) is an inhibitor of cytochrome P450 isoforms <Emphasis><GlossaryTermRef href="CDR0000045733" dictionary="Cancer.gov" audience="Patient">in vitro</GlossaryTermRef></Emphasis>. Because many anticancer therapies are metabolized by these <GlossaryTermRef href="CDR0000046081" dictionary="Cancer.gov" audience="Patient">enzymes</GlossaryTermRef>, highly concentrated CBD oils used concurrently could potentially increase the <GlossaryTermRef href="CDR0000445093" dictionary="Cancer.gov" audience="Patient">toxicity</GlossaryTermRef> or decrease the effectiveness of these therapies.<Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/></Para><Para id="_156">Since <ScientificName>Cannabis</ScientificName> smoke contains many of the same components as <GlossaryTermRef href="CDR0000439432" dictionary="Cancer.gov" audience="Patient">tobacco</GlossaryTermRef> smoke, there are valid concerns about the adverse <GlossaryTermRef href="CDR0000045852" dictionary="Cancer.gov" audience="Patient">pulmonary</GlossaryTermRef> effects of <GlossaryTermRef href="CDR0000044600" dictionary="Cancer.gov" audience="Patient">inhaled</GlossaryTermRef>  <Emphasis>Cannabis</Emphasis>. A longitudinal study in a noncancer population evaluated repeated measurements of pulmonary function over  20 years in 5,115 men and women whose smoking histories were known.<Reference refidx="8"/> 

While tobacco exposure was associated with decreased pulmonary function, the investigators concluded that occasional and low-cumulative <ScientificName>Cannabis</ScientificName> use was not associated with adverse effects on pulmonary function (forced expiratory volume in the first second of expiration [FEV1] and forced vital capacity [FVC]).</Para></SummarySection><SummarySection id="_353"><Title>Interactions With Conventional Cancer Therapies</Title><Para id="_354">The potential for cytochrome P450 interactions with highly concentrated oil preparations of delta-9-tetrahydrocannabinol and/or cannabidiol is a concern.<Reference refidx="9"/> Few pharmacokinetic interaction studies have been conducted with <ScientificName>Cannabis</ScientificName> or cannabinoids and conventional cancer therapies. There is insufficient clinical evidence and concern to support the belief  that relatively small amounts of active cannabinoids can substantially impact  <GlossaryTermRef href="CDR0000046173" dictionary="Cancer.gov" audience="Patient">metabolism</GlossaryTermRef> of relatively large <GlossaryTermRef href="CDR0000044664" dictionary="Cancer.gov" audience="Patient">doses</GlossaryTermRef> of <GlossaryTermRef href="CDR0000045214" dictionary="Cancer.gov" audience="Patient">chemotherapy</GlossaryTermRef> drugs.</Para><Para id="_355">An Israeli retrospective observational study assessed the impact of <ScientificName>Cannabis</ScientificName> use during nivolumab immunotherapy.<Reference refidx="10"/> One hundred forty patients with advanced melanoma, non-small cell lung cancer, and renal cell carcinoma received the checkpoint inhibitor nivolumab (89 patients received nivolumab alone and  51 patients received nivolumab plus <ScientificName>Cannabis</ScientificName>). In a multivariate model, <ScientificName>Cannabis</ScientificName> was the only significant factor that reduced the response rate to  immunotherapy (37.5% in patients who received nivolumab alone compared with 15.9% in patients who received  nivolumab plus <ScientificName>Cannabis</ScientificName> [odds ratio, 3.13;  95% confidence interval, 1.24–8.1; <Emphasis>P</Emphasis> = .016]). There was no difference in progression-free survival or overall survival. A subsequent prospective observational study from the same investigators followed 102 patients with metastatic cancers initiating immunotherapy.<Reference refidx="11"/>[<LOERef href="CDR0000335136" dictionary="NotSet" audience="Health professional">Level of evidence: 2Dii</LOERef>] Sixty-eight patients received immunotherapy alone while 34 patients used <ScientificName>Cannabis</ScientificName> during immunotherapy. Over half of the patients in each group had stage IV non-small cell lung cancer. <ScientificName>Cannabis</ScientificName> users were less likely to receive immunotherapy as a first-line intervention (24%) compared with  nonusers (46%) (<Emphasis>P</Emphasis> = .03). <ScientificName>Cannabis</ScientificName> users showed a significantly lower percentage of clinical benefit (39% of <ScientificName>Cannabis</ScientificName> users with complete or partial responses or stable disease compared with 59% of nonusers [<Emphasis>P</Emphasis> = .035]). In this <GlossaryTermRef href="CDR0000390238" dictionary="Cancer.gov" audience="Patient">analysis</GlossaryTermRef>, the median time to tumor progression was 3.4 months in <ScientificName>Cannabis</ScientificName> users compared with 13.1 months in nonusers and the overall survival was 6.4 months in <ScientificName>Cannabis</ScientificName> users compared with 28.5 months in nonusers. The investigators also noted that <ScientificName>Cannabis</ScientificName> users reported a lower rate of overall treatment-related adverse experiences compared with nonusers, with fewer immune-related adverse events (<Emphasis>P</Emphasis> = .057). The investigators postulated that this finding may be related to the  possible immunosuppressive effects of <ScientificName>Cannabis</ScientificName> and concluded that <ScientificName>Cannabis</ScientificName> consumption should be carefully considered in patients with advanced malignancies who are treated with immunotherapy. Limitations noted by the authors that may be confounders in this analysis include the observational nature of the study, the relatively small sample size, and the high heterogeneity of the participants.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="8972919">Adams IB, Martin BR: Cannabis: pharmacology and toxicology in animals and humans. Addiction 91 (11): 1585-614, 1996.</Citation><Citation idx="2">Grotenhermen F, Russo E, eds.: Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential. The Haworth Press, 2002.</Citation><Citation idx="3" PMID="17136871">Sutton IR, Daeninck P: Cannabinoids in the management of intractable chemotherapy-induced nausea and vomiting and cancer-related pain. J Support Oncol 4 (10): 531-5, 2006 Nov-Dec.</Citation><Citation idx="4" PMID="14570037">Guzmán M: Cannabinoids: potential anticancer agents. Nat Rev Cancer 3 (10): 745-55, 2003.</Citation><Citation idx="5" PMID="21821735">Yamaori S, Okamoto Y, Yamamoto I, et al.: Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos 39 (11): 2049-56, 2011.</Citation><Citation idx="6" PMID="23318708">Jiang R, Yamaori S, Okamoto Y, et al.: Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19. Drug Metab Pharmacokinet 28 (4): 332-8, 2013.</Citation><Citation idx="7" PMID="36849134">Guedon M, Le Bozec A, Brugel M, et al.: Cannabidiol-drug interaction in cancer patients: A retrospective study in a real-life setting. Br J Clin Pharmacol 89 (7): 2322-2328, 2023.</Citation><Citation idx="8" PMID="22235088">Pletcher MJ, Vittinghoff E, Kalhan R, et al.: Association between marijuana exposure and pulmonary function over 20 years. JAMA 307 (2): 173-81, 2012.</Citation><Citation idx="9">Kocis PT, Vrana KE: Delta-9-tetrahydrocannabinol and cannabidiol drug-drug interactions. Med Cannabis Cannabinoids  3 (1): 61-73, 2020.</Citation><Citation idx="10" PMID="30670598">Taha T, Meiri D, Talhamy S, et al.: Cannabis Impacts Tumor Response Rate to Nivolumab in Patients with Advanced Malignancies. Oncologist 24 (4): 549-554, 2019.</Citation><Citation idx="11" PMID="32872248">Bar-Sela G, Cohen I, Campisi-Pinto S, et al.: Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome. Cancers (Basel) 12 (9): , 2020.</Citation></ReferenceSection></SummarySection><SummarySection id="_13"><Title>Summary of the Evidence for <Emphasis>Cannabis</Emphasis> and Cannabinoids</Title><Para id="_14">To assist readers in evaluating the results of human studies of integrative, alternative, and complementary therapies for people with <GlossaryTermRef href="CDR0000045333" dictionary="Cancer.gov" audience="Patient">cancer</GlossaryTermRef>, the strength of the evidence (i.e., the <GlossaryTermRef href="CDR0000446533" dictionary="Cancer.gov" audience="Patient">levels of evidence</GlossaryTermRef>) associated with each type of treatment is provided whenever possible. To qualify for a level of evidence <GlossaryTermRef href="CDR0000390238" dictionary="Cancer.gov" audience="Patient">analysis</GlossaryTermRef>, a study must:</Para><ItemizedList id="_70" Style="bullet"><ListItem>Be published in a <GlossaryTermRef href="CDR0000537399" dictionary="Cancer.gov" audience="Patient">peer-reviewed scientific journal</GlossaryTermRef>.</ListItem><ListItem>Report on <GlossaryTermRef href="CDR0000043985" dictionary="Cancer.gov" audience="Patient">therapeutic</GlossaryTermRef> <GlossaryTermRef href="CDR0000467853" dictionary="Cancer.gov" audience="Patient">outcome</GlossaryTermRef> or outcomes, such as <GlossaryTermRef href="CDR0000046634" dictionary="Cancer.gov" audience="Patient">tumor</GlossaryTermRef> <GlossaryTermRef href="CDR0000044085" dictionary="Cancer.gov" audience="Patient">response</GlossaryTermRef>, improvement in survival, or measured improvement in <GlossaryTermRef href="CDR0000045417" dictionary="Cancer.gov" audience="Patient">quality of life</GlossaryTermRef>.</ListItem><ListItem>Describe <GlossaryTermRef href="CDR0000044168" dictionary="Cancer.gov" audience="Patient">clinical</GlossaryTermRef> findings in sufficient detail for a meaningful evaluation to be made.</ListItem></ItemizedList><Para id="_92">Separate levels of evidence scores are assigned to qualifying human studies on the basis of statistical strength of the study design and scientific strength of the treatment outcomes (i.e., <GlossaryTermRef href="CDR0000346519" dictionary="Cancer.gov" audience="Patient">end points</GlossaryTermRef>) measured. The resulting two scores are then combined to produce an overall score. For an explanation of possible scores and additional information about levels of evidence analysis of Complementary and Alternative Medicine (CAM) treatments for people with cancer, see <SummaryRef href="CDR0000256874" url="/publications/pdq/levels-evidence/cam">Levels of Evidence for Human Studies of Integrative, Alternative, and Complementary Therapies</SummaryRef>.</Para><ItemizedList id="_90" Style="simple"><ListTitle>Cannabinoids</ListTitle><ListItem>Several <GlossaryTermRef href="CDR0000044014" dictionary="Cancer.gov" audience="Patient">controlled clinical trials</GlossaryTermRef> have been performed, and <GlossaryTermRef href="CDR0000691484" dictionary="Cancer.gov" audience="Patient">meta-analyses</GlossaryTermRef> of these support a beneficial effect of cannabinoids (<GlossaryTermRef href="CDR0000045240" dictionary="Cancer.gov" audience="Patient">dronabinol</GlossaryTermRef> and nabilone) on <GlossaryTermRef href="CDR0000045214" dictionary="Cancer.gov" audience="Patient">chemotherapy</GlossaryTermRef>-induced <GlossaryTermRef href="CDR0000390302" dictionary="Cancer.gov" audience="Patient">nausea</GlossaryTermRef> and <GlossaryTermRef href="CDR0000390324" dictionary="Cancer.gov" audience="Patient">vomiting</GlossaryTermRef> (N/V) compared with <GlossaryTermRef href="CDR0000046688" dictionary="Cancer.gov" audience="Patient">placebo</GlossaryTermRef>.    Both dronabinol and nabilone are approved by the <GlossaryTermRef href="CDR0000454785" dictionary="Cancer.gov" audience="Patient">U.S. Food and Drug Administration</GlossaryTermRef> for the <GlossaryTermRef href="CDR0000439419" dictionary="Cancer.gov" audience="Patient">prevention</GlossaryTermRef> or treatment of chemotherapy-induced N/V in patients with cancer but not for other <GlossaryTermRef href="CDR0000269453" dictionary="Cancer.gov" audience="Patient">symptom management</GlossaryTermRef>.</ListItem></ItemizedList><ItemizedList id="_91" Style="bullet"><ListTitle>Cannabis</ListTitle><ListItem>There have been ten clinical trials on the use of <GlossaryTermRef href="CDR0000044600" dictionary="Cancer.gov" audience="Patient">inhaled</GlossaryTermRef> <ScientificName><GlossaryTermRef href="CDR0000716285" dictionary="Cancer.gov" audience="Patient">Cannabis</GlossaryTermRef></ScientificName> in cancer patients that can be divided into two groups.  In one group, four small studies assessed <GlossaryTermRef href="CDR0000046084" dictionary="Cancer.gov" audience="Patient">antiemetic</GlossaryTermRef> activity, but each explored a different patient population and chemotherapy <GlossaryTermRef href="CDR0000045864" dictionary="Cancer.gov" audience="Patient">regimen</GlossaryTermRef>.  One study demonstrated no effect, the second study showed a positive effect versus placebo, and the report of the third study did not provide enough information to characterize the overall outcome as positive or neutral.  Consequently, there are insufficient data to provide an overall level of evidence <GlossaryTermRef href="CDR0000430407" dictionary="Cancer.gov" audience="Patient">assessment</GlossaryTermRef> for the use of <ScientificName>Cannabis</ScientificName> for chemotherapy-induced N/V. Apparently, there are no published controlled clinical trials on  the use of inhaled <ScientificName>Cannabis</ScientificName> for other cancer-related or cancer treatment–related <GlossaryTermRef href="CDR0000045022" dictionary="Cancer.gov" audience="Patient">symptoms</GlossaryTermRef>.</ListItem><ListItem>An increasing number of trials are evaluating the oromucosal <GlossaryTermRef href="CDR0000478733" dictionary="Cancer.gov" audience="Patient">administration</GlossaryTermRef> of <ScientificName>Cannabis</ScientificName> plant <GlossaryTermRef href="CDR0000407760" dictionary="Cancer.gov" audience="Patient">extract</GlossaryTermRef> with fixed concentrations of cannabinoid components, with national drug regulatory agencies in Canada and in some European countries that issue approval for cancer pain.</ListItem><ListItem>At present, there is insufficient evidence to recommend  inhaling  <ScientificName>Cannabis</ScientificName> as a treatment for cancer-related symptoms or cancer treatment–related symptoms or cancer treatment-related <GlossaryTermRef href="CDR0000046580" dictionary="Cancer.gov" audience="Patient">side effects</GlossaryTermRef>; however, additional research is needed.</ListItem></ItemizedList></SummarySection><SummarySection id="_15"><SectMetaData><SectionType>Changes to summary</SectionType></SectMetaData><Title>Latest Updates to This Summary (05/13/2025)</Title><Para id="_16">The <GlossaryTermRef href="CDR0000044271" dictionary="Cancer.gov" audience="Patient">PDQ</GlossaryTermRef> <GlossaryTermRef href="CDR0000045333" dictionary="Cancer.gov" audience="Patient">cancer</GlossaryTermRef> information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.</Para><Para id="_410"><Strong><SummaryRef href="CDR0000683767#_3" url="/about-cancer/treatment/cam/hp/cannabis-pdq">General Information</SummaryRef></Strong></Para><Para id="_409">Added <SummaryRef href="CDR0000683767#_408" url="/about-cancer/treatment/cam/hp/cannabis-pdq">text</SummaryRef> about the findings from a multicenter survey on perceptions, prevalence, and patterns of <ScientificName>Cannabis</ScientificName> use among 13,180 patients with various cancers treated at 12 National Cancer Institute-designated cancer centers (cited Ellison et al. as reference 4).</Para><Para id="_disclaimerHP_3">This summary is written and maintained by the <ExternalRef xref="https://www.cancer.gov/publications/pdq/editorial-boards/cam">PDQ Integrative, Alternative, and Complementary Therapies Editorial Board</ExternalRef>, which is
editorially independent of NCI.  The summary reflects an independent review of
the literature and does not represent a policy statement of NCI or NIH.  More
information about summary policies and the role of the PDQ Editorial Boards  in
maintaining the PDQ summaries can be found on the <SummaryRef href="CDR0000683767#_AboutThis_1" url="/about-cancer/treatment/cam/hp/cannabis-pdq">About This PDQ Summary</SummaryRef> and <ExternalRef xref="https://www.cancer.gov/publications/pdq">PDQ® Cancer Information for Health Professionals</ExternalRef> pages.
</Para></SummarySection><SummarySection id="_AboutThis_1"><Title>About This PDQ Summary</Title><SummarySection id="_AboutThis_2"><Title>Purpose of This Summary</Title><Para id="_AboutThis_3">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the use of  Cannabis and cannabinoids in the treatment of people with cancer. It is intended as a resource to inform and assist clinicians in the care of their patients.  It does not provide formal guidelines or recommendations for making health care decisions.</Para></SummarySection><SummarySection id="_AboutThis_4"><Title>Reviewers and Updates</Title><Para id="_AboutThis_5">This summary is reviewed regularly and updated as necessary by the <ExternalRef xref="https://www.cancer.gov/publications/pdq/editorial-boards/cam">PDQ Integrative, Alternative, and Complementary Therapies Editorial Board</ExternalRef>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para><Para id="_AboutThis_22"> Board members review recently published articles each month to determine whether an article should:</Para><ItemizedList id="_AboutThis_6" Style="bullet"><ListItem>be discussed at a meeting,</ListItem><ListItem>be cited with text, or</ListItem><ListItem>replace or update an existing article that is already cited.</ListItem></ItemizedList><Para id="_AboutThis_7">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.</Para><Para id="_AboutThis_9">Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's <ExternalRef xref="https://www.cancer.gov/contact/email-us">Email Us</ExternalRef>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</Para></SummarySection><SummarySection id="_AboutThis_10"><Title>Levels of Evidence</Title><Para id="_AboutThis_11">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Integrative, Alternative, and Complementary Therapies Editorial Board uses a <SummaryRef href="CDR0000256874" url="/publications/pdq/levels-evidence/cam">formal evidence ranking system</SummaryRef> in developing its level-of-evidence designations.</Para></SummarySection><SummarySection id="_AboutThis_12"><Title>Permission to Use This Summary</Title><Para id="_AboutThis_13">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”</Para><Para id="_AboutThis_14">The preferred citation for this PDQ summary is:</Para><Para id="_AboutThis_15">PDQ® Integrative, Alternative, and Complementary Therapies Editorial Board. PDQ Cannabis and Cannabinoids. Bethesda, MD: National Cancer Institute. Updated  &lt;MM/DD/YYYY&gt;. Available at: <ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq">https://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq</ExternalRef>.  Accessed &lt;MM/DD/YYYY&gt;. [PMID: 26389198]</Para><Para id="_AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <ExternalRef xref="https://visualsonline.cancer.gov/">Visuals Online</ExternalRef>, a collection of over 2,000 scientific images.

</Para></SummarySection><SummarySection id="_AboutThis_17"><Title>Disclaimer</Title><Para id="_AboutThis_19">The information in these summaries should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <ExternalRef xref="https://www.cancer.gov/about-cancer/managing-care">Managing Cancer Care</ExternalRef> page.</Para></SummarySection><SummarySection id="_AboutThis_20"><Title>Contact Us</Title><Para id="_AboutThis_21">More information about contacting us or receiving help with the Cancer.gov website can be found on our <ExternalRef xref="https://www.cancer.gov/contact">Contact Us for Help</ExternalRef> page. Questions can also be submitted to Cancer.gov through the website’s <ExternalRef xref="https://www.cancer.gov/contact/email-us">Email Us</ExternalRef>.</Para></SummarySection></SummarySection><DateFirstPublished>2011-03-16</DateFirstPublished><DateLastModified>2025-05-13</DateLastModified></Summary>
